Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors
DOYLESTOWN, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medicinal chemistry company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed pharmaceutical and biotechnology industry veteran Dr. Tage Honoré as the Chairman of the Company’s Board of Advisors.
Dr. Honoré is a world-renowned pharma and biotechnology executive, entrepreneur, and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy (HRT), learning disorders, osteoporosis, Parkinson’s disease, stroke, and schizophrenia. Among his many accomplishments is the discovery of the AMPA subtype of excitatory amino acid receptors, as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system (CNS).
“Dr. Honoré’s successes are attributed to his ability to translate science to product opportunities and his understanding of the need to integrate research, clinic, market and financial stakeholders. We are pleased and excited to have him on board. His clinical drug development experience and knowledge in the CNS and PNS space is invaluable and timely to our current efforts to head towards the clinic with KLS-13019,” said Dean Petkanas, CEO of Kannalife.
Additionally, Dr. Honoré has published more than 100 scientific papers, is the inventor on 23 patents, and has championed 40 drugs to progress from idea to clinical development, including Gabatril (tiagabine) and other novel compounds that entered the prescription drug market.
The organizational models Dr. Honoré developed to obtain record pipeline productivity in several companies are key to his business achievements. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research at Novartis Pharma Inc; VP Discovery Research at Purdue Pharma LP; and President and CEO at Aestus Therapeutics Inc.
Dr. Honoré has a master’s degree in pharmaceutical science and doctoral degrees in medicinal chemistry and neurobiology. He also has business training from Harvard Business School and European Management Centre.
“Kannalife is uniquely positioned to become a major player in the field of neurodegeneration, focusing on chemotherapy-induced peripheral neuropathy (CIPN) where treatment is hampered by abuse potential and/or lack of efficacy. In addition, a number of neurodegenerative diseases such as hepatic encephalopathy (HE) connected to different degrees of liver failure and traumatic brain injury (TBI) caused by repetitive concussions simply lack targeted and efficacious therapy and may benefit from the reduction of oxidative stress mediated by KLS-13019,” said Dr. Honoré.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
Atopidine™ is Kannalife’s novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.
KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine™ have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, the Company’s position, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
DOYLESTOWN, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medicinal chemistry company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed pharmaceutical and biotechnology industry veteran Dr. Tage Honoré as the Chairman of the Company’s Board of Advisors.
Dr. Honoré is a world-renowned pharma and biotechnology executive, entrepreneur, and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy (HRT), learning disorders, osteoporosis, Parkinson’s disease, stroke, and schizophrenia. Among his many accomplishments is the discovery of the AMPA subtype of excitatory amino acid receptors, as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system (CNS).
“Dr. Honoré’s successes are attributed to his ability to translate science to product opportunities and his understanding of the need to integrate research, clinic, market and financial stakeholders. We are pleased and excited to have him on board. His clinical drug development experience and knowledge in the CNS and PNS space is invaluable and timely to our current efforts to head towards the clinic with KLS-13019,” said Dean Petkanas, CEO of Kannalife.
Additionally, Dr. Honoré has published more than 100 scientific papers, is the inventor on 23 patents, and has championed 40 drugs to progress from idea to clinical development, including Gabatril (tiagabine) and other novel compounds that entered the prescription drug market.
The organizational models Dr. Honoré developed to obtain record pipeline productivity in several companies are key to his business achievements. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research at Novartis Pharma Inc; VP Discovery Research at Purdue Pharma LP; and President and CEO at Aestus Therapeutics Inc.
Dr. Honoré has a master’s degree in pharmaceutical science and doctoral degrees in medicinal chemistry and neurobiology. He also has business training from Harvard Business School and European Management Centre.
“Kannalife is uniquely positioned to become a major player in the field of neurodegeneration, focusing on chemotherapy-induced peripheral neuropathy (CIPN) where treatment is hampered by abuse potential and/or lack of efficacy. In addition, a number of neurodegenerative diseases such as hepatic encephalopathy (HE) connected to different degrees of liver failure and traumatic brain injury (TBI) caused by repetitive concussions simply lack targeted and efficacious therapy and may benefit from the reduction of oxidative stress mediated by KLS-13019,” said Dr. Honoré.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
Atopidine™ is Kannalife’s novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.
KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine™ have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, the Company’s position, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
DOYLESTOWN, Pa., June 30, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued patents in Switzerland (CH), Germany (DE), France (FR), United Kingdom (GB), Ireland (IE), Italy (IT), Spain (ES), Belgium (BE), Sweden (SE), Turkey (TR), the Netherlands (NL), and Denmark (DK) for its patent known as WO2015/106108A2 and titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”).
With the PCT Patent, along with Kannalife’s novel lead drug candidate KLS-13019 and its other novel therapeutic agents like Atopidine™, Kannalife now has near-global coverage in the top pharmaceutical markets in the world.
In 2018, Europe was responsible for 23.2 percent of the world’s pharmaceutical sales.1 The size of the market in the European Union Five is expected to grow by 25 percent between 2017-2022,2 with experts predicting the market will reach over $226 billion in total from pharmaceutical market sales.3
“We have a very live and viable leading drug candidate in KLS-13019, which is a non-opioid based solution to treating neuropathic pain. The remarkable capabilities behind the science of KLS-13019 and its sister compounds are their ability to effectively break the blood-barrier and their strong neuroprotective and anti-inflammatory properties,” said Dean Petkanas, CEO of Kannalife. “These key pharmacological benefits open the door to a host of other peripheral and central nervous system diseases and disorders as well.”
KLS-13019 leads Kannalife’s intellectual property portfolio of novel monotherapeutic molecules (“KLS Family”), which have been proven capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress, and neurodegenerative disorders. KLS-13019 is the Company’s leading candidate to treat chemotherapy-induced peripheral neuropathy (CIPN), a disorder that currently has no FDA approved drugs for treatment. Current off-label prescription of opioids, a leading agitator of overdose deaths and addiction, is the model of treatment.
The PCT Patent grants mark the nineteenth (19th) patent that Kannalife has received to date worldwide. Of the nineteen (19) patents issued to Kannalife, two (2) are U.S. patents, and seventeen (17) are foreign patents. The two (2) U.S. patents are:
U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
U.S. Patent 10,004,722 “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols”
The seventeen (17) foreign patents claim priority to Kannalife’s original 2014 U.S. filing through international application PCT/US2015/010827, which was published as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
Of the seventeen (17) foreign patents, twelve (12) of them are granted for the PCT Patent in the European territories of BE, CH, DE, DK, ES, FR, GB, IE, IT, NL, SE and TR. The remaining five foreign patents are:
Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
Chinese Patent CN106456573B “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
Australian Patent AU2015204609B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” and
European Patent EP3094318B1 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
The Company recently completed a STTR phase 1 study funded by a grant from the National Institutes of Health’s National Institute on Drug Abuse. The study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative monotherapeutic in the prevention and reversal of CIPN.
Kannalife also has national phase patent applications based on the PCT Patent application pending in Canada, Brazil and India.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
Atopidine™ is Kannalife’s novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.
KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine™ have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
DOYLESTOWN, Pa., June 30, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued patents in Switzerland (CH), Germany (DE), France (FR), United Kingdom (GB), Ireland (IE), Italy (IT), Spain (ES), Belgium (BE), Sweden (SE), Turkey (TR), the Netherlands (NL), and Denmark (DK) for its patent known as WO2015/106108A2 and titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”).
With the PCT Patent, along with Kannalife’s novel lead drug candidate KLS-13019 and its other novel therapeutic agents like Atopidine™, Kannalife now has near-global coverage in the top pharmaceutical markets in the world.
In 2018, Europe was responsible for 23.2 percent of the world’s pharmaceutical sales.1 The size of the market in the European Union Five is expected to grow by 25 percent between 2017-2022,2 with experts predicting the market will reach over $226 billion in total from pharmaceutical market sales.3
“We have a very live and viable leading drug candidate in KLS-13019, which is a non-opioid based solution to treating neuropathic pain. The remarkable capabilities behind the science of KLS-13019 and its sister compounds are their ability to effectively break the blood-barrier and their strong neuroprotective and anti-inflammatory properties,” said Dean Petkanas, CEO of Kannalife. “These key pharmacological benefits open the door to a host of other peripheral and central nervous system diseases and disorders as well.”
KLS-13019 leads Kannalife’s intellectual property portfolio of novel monotherapeutic molecules (“KLS Family”), which have been proven capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress, and neurodegenerative disorders. KLS-13019 is the Company’s leading candidate to treat chemotherapy-induced peripheral neuropathy (CIPN), a disorder that currently has no FDA approved drugs for treatment. Current off-label prescription of opioids, a leading agitator of overdose deaths and addiction, is the model of treatment.
The PCT Patent grants mark the nineteenth (19th) patent that Kannalife has received to date worldwide. Of the nineteen (19) patents issued to Kannalife, two (2) are U.S. patents, and seventeen (17) are foreign patents. The two (2) U.S. patents are:
U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
U.S. Patent 10,004,722 “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols”
The seventeen (17) foreign patents claim priority to Kannalife’s original 2014 U.S. filing through international application PCT/US2015/010827, which was published as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
Of the seventeen (17) foreign patents, twelve (12) of them are granted for the PCT Patent in the European territories of BE, CH, DE, DK, ES, FR, GB, IE, IT, NL, SE and TR. The remaining five foreign patents are:
Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
Chinese Patent CN106456573B “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
Australian Patent AU2015204609B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” and
European Patent EP3094318B1 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
The Company recently completed a STTR phase 1 study funded by a grant from the National Institutes of Health’s National Institute on Drug Abuse. The study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative monotherapeutic in the prevention and reversal of CIPN.
Kannalife also has national phase patent applications based on the PCT Patent application pending in Canada, Brazil and India.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
Atopidine™ is Kannalife’s novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.
KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine™ have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors
DOYLESTOWN, Pa., June 02, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Company’s Board of Advisors.
Mr. Tormey’s most recent position was CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease. For over four decades, Mr. Tormey has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known life sciences companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson).
“It’s really great to have Terry join our corporate advisory board and team of experts at Kannalife. His experience, vision and extraordinary body of knowledge in the life sciences industry come at a perfect time for us as we start to design our commercialization and distribution plan for Atopidine™,” said Dean Petkanas, CEO of Kannalife.
“I am honored to serve as an advisor to Kannalife. They have remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN), which, when approved, will help improve the lives of hundreds of thousands of patients,” Tormey said.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
Atopidine™ is Kannalife’s novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.
KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
DOYLESTOWN, Pa., June 02, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Company’s Board of Advisors.
Mr. Tormey’s most recent position was CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease. For over four decades, Mr. Tormey has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known life sciences companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson).
“It’s really great to have Terry join our corporate advisory board and team of experts at Kannalife. His experience, vision and extraordinary body of knowledge in the life sciences industry come at a perfect time for us as we start to design our commercialization and distribution plan for Atopidine™,” said Dean Petkanas, CEO of Kannalife.
“I am honored to serve as an advisor to Kannalife. They have remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN), which, when approved, will help improve the lives of hundreds of thousands of patients,” Tormey said.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
Atopidine™ is Kannalife’s novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.
KLS-13019 is Kannalife’s leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD
DOYLESTOWN, Pa., April 14, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation in one of its studies.
The Company has conducted scientific comparisons that have been made between two substances: cannabidiol (CBD), a non-psychoactive component of Cannabis, and Atopidine™, a novel, small molecule that has been shown in pre-clinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used to monitor the comparison of the two substances. Although both compounds were effective in preventing the release of TNF-alpha (TNFα), only Atopidine™ was found to be effective in preventing the release of IL-1-beta (IL-1β) from human epidermal cells. The current experiments suggest that Atopidine™ may be more effective than CBD in preventing inflammatory responses relevant to UVB-radiation.
“We believe our approach to taking the good from CBD and improving on it as a therapeutic is seen in our discovery of novel CBD inspired therapeutic compounds like Atopidine™. Innovation and technology usually improves on nature’s limitations. We believe such is the case with Atopidine™, as a potentially better anti-inflammatory topical solution than CBD,” said Dean Petkanas, CEO of Kannalife.
The market demand for products that defend against harmful UVB and UVA radiation has surged in recent years. Sun care products have moved from solely being intended for skin care to being a multifunctional first line of defense to sun exposure. The global sun care market has witnessed significant growth and is projected to reach $24.9 billion USD by 20241, while the global skin care products market is projected to reach $183.03 billion USD by 2025.2
The Company is hoping to have Atopidine™, also known as Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (LEA), as a finished product by the end of 2020 for commercial use as an emollient to address a number of skin care and personal care needs.
About Atopidine™ Atopidine™ is a proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of skin care, anti-inflammatory, antioxidant, and personal care needs. Atopidine™ has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
DOYLESTOWN, Pa., April 14, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation in one of its studies.
The Company has conducted scientific comparisons that have been made between two substances: cannabidiol (CBD), a non-psychoactive component of Cannabis, and Atopidine™, a novel, small molecule that has been shown in pre-clinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used to monitor the comparison of the two substances. Although both compounds were effective in preventing the release of TNF-alpha (TNFα), only Atopidine™ was found to be effective in preventing the release of IL-1-beta (IL-1β) from human epidermal cells. The current experiments suggest that Atopidine™ may be more effective than CBD in preventing inflammatory responses relevant to UVB-radiation.
“We believe our approach to taking the good from CBD and improving on it as a therapeutic is seen in our discovery of novel CBD inspired therapeutic compounds like Atopidine™. Innovation and technology usually improves on nature’s limitations. We believe such is the case with Atopidine™, as a potentially better anti-inflammatory topical solution than CBD,” said Dean Petkanas, CEO of Kannalife.
The market demand for products that defend against harmful UVB and UVA radiation has surged in recent years. Sun care products have moved from solely being intended for skin care to being a multifunctional first line of defense to sun exposure. The global sun care market has witnessed significant growth and is projected to reach $24.9 billion USD by 20241, while the global skin care products market is projected to reach $183.03 billion USD by 2025.2
The Company is hoping to have Atopidine™, also known as Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (LEA), as a finished product by the end of 2020 for commercial use as an emollient to address a number of skin care and personal care needs.
About Atopidine™ Atopidine™ is a proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of skin care, anti-inflammatory, antioxidant, and personal care needs. Atopidine™ has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™
DOYLESTOWN, Pa., April 01, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark application for the mark, “Atopidine”.
The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (“LEA”), the International Nomenclature of Cosmetic Ingredient (INCI) assigned name for the Company’s patented monotherapeutic compound KLS-13022.
In pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFα, Il-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and currently among the targets believed to be creating the cytokine storm in SARS-CoA-2 (“COVID-19”).
The Company is hoping to have Atopidine™ as a finished product by the end of 2020 for commercial use as an emollient to address a number of skin care and personal care needs.
Due to rising concerns regarding skin problems, various synthetic and natural products are driving the skin care industry. According to a recent report, the global skin care products market size is projected to reach $183.03 billion USD by 2025.1
“We are currently testing the anti-inflammatory and antioxidant potential of our patented compound Atopidine™ versus Betamethasone, a well-known corticosteroid and cannabidiol (CBD). When these studies are completed, we believe we will have a superior compound in treating keratinocyte-derived cytokine related skin disorders. After that, we would be really interested to see how Atopidine™ works with and compares to Kevzara (sarilumab) from Sanofi-Regeneron and Roche’s Actemra (tocilizumab), both IL-6 human monoclonal antibodies used in treating severe rheumatoid arthritis,” said Dean Petkanas, CEO of Kannalife.
About KLS-13022 KLS-13022 is a proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of skin care, anti-inflammatory, antioxidant, and personal care needs. KLS-13022 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
References Grand View Research Skin Care Products Market Worth $183.03 Billion By 2025 | CAGR: 4.4%
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
DOYLESTOWN, Pa., April 01, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark application for the mark, “Atopidine”.
The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (“LEA”), the International Nomenclature of Cosmetic Ingredient (INCI) assigned name for the Company’s patented monotherapeutic compound KLS-13022.
In pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFα, Il-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and currently among the targets believed to be creating the cytokine storm in SARS-CoA-2 (“COVID-19”).
The Company is hoping to have Atopidine™ as a finished product by the end of 2020 for commercial use as an emollient to address a number of skin care and personal care needs.
Due to rising concerns regarding skin problems, various synthetic and natural products are driving the skin care industry. According to a recent report, the global skin care products market size is projected to reach $183.03 billion USD by 2025.1
“We are currently testing the anti-inflammatory and antioxidant potential of our patented compound Atopidine™ versus Betamethasone, a well-known corticosteroid and cannabidiol (CBD). When these studies are completed, we believe we will have a superior compound in treating keratinocyte-derived cytokine related skin disorders. After that, we would be really interested to see how Atopidine™ works with and compares to Kevzara (sarilumab) from Sanofi-Regeneron and Roche’s Actemra (tocilizumab), both IL-6 human monoclonal antibodies used in treating severe rheumatoid arthritis,” said Dean Petkanas, CEO of Kannalife.
About KLS-13022 KLS-13022 is a proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of skin care, anti-inflammatory, antioxidant, and personal care needs. KLS-13022 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
References Grand View Research Skin Care Products Market Worth $183.03 Billion By 2025 | CAGR: 4.4%
Public Relations: Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent
DOYLESTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that China has issued the Company, Chinese Patent CN106456573B (the “Patent”) specific to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” which further bolsters the Company’s global patent portfolio of cannabidiol (CBD)-like molecules. The Company anticipates receipt of patent grants from the EU and Australia sometime during the first and second quarters of 2020.
Kannalife’s intellectual property estate of CBD-like molecules (“KLS Family”), which is led by KLS-13019, are capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress and neurodegenerative disorders. Under the Patent, Kannalife will further explore the application and potential of new molecular entities (NMEs) across epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).
“Kannalife’s lead candidate, KLS-13019, provides an alternative to cannabidiol throughout major pharmaceutical markets with its proprietary molecule that has improved potency, selectivity, safety, bioavailability, and efficacy,” stated William Kinney, PhD, Chief Scientific Officer of Kannalife.
The issued Patent is part of the dramatically increasing intellectual property estate of the global WIPO/PCT Patent WO2015/106108A2 titled “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”). Since the 2015 filing of the initial PCT Patent, the Company has received patent approval across three significant global markets:
U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
U.S. Patent 10,004,722 “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols”
Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” and
Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
“China is an increasingly open marketplace whose National Medical Products Administration recognizes and supports innovative science and medical approaches to expand the treatment options available to patients,” said Dean Petkanas, CEO of Kannalife. “This has further fueled the potential of the Chinese pharmaceutical industry, which rapidly grew to become the world’s second-biggest drug market in 2016 and registered sales of $137 billion in 2018. Looking forward, China is projected to reach half the size of America’s market by 2030 versus the current 25 percent comparison.1”
Currently, Kannalife’s leading drug candidate KLS-13019, a CBD-like molecule, is being investigated in preclinical studies for the potential treatment of neuropathic pain. Through extensive research and testing, Kannalife has identified KLS-13019 as a potent, non-opioid alternative to the frontline treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Additionally, Kannalife’s application for patent protection of its intellectual property has been accepted in the European Union (EU) and Australia. The Company is awaiting notice from Canada, Brazil and India for notice of acceptance.
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Mike Mulvihill, Senior Counsel of Padilla P: 804-334-2292 E: mike.mulvihill@padillaco.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
DOYLESTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that China has issued the Company, Chinese Patent CN106456573B (the “Patent”) specific to “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” which further bolsters the Company’s global patent portfolio of cannabidiol (CBD)-like molecules. The Company anticipates receipt of patent grants from the EU and Australia sometime during the first and second quarters of 2020.
Kannalife’s intellectual property estate of CBD-like molecules (“KLS Family”), which is led by KLS-13019, are capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress and neurodegenerative disorders. Under the Patent, Kannalife will further explore the application and potential of new molecular entities (NMEs) across epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).
“Kannalife’s lead candidate, KLS-13019, provides an alternative to cannabidiol throughout major pharmaceutical markets with its proprietary molecule that has improved potency, selectivity, safety, bioavailability, and efficacy,” stated William Kinney, PhD, Chief Scientific Officer of Kannalife.
The issued Patent is part of the dramatically increasing intellectual property estate of the global WIPO/PCT Patent WO2015/106108A2 titled “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”). Since the 2015 filing of the initial PCT Patent, the Company has received patent approval across three significant global markets:
U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy”
U.S. Patent 10,004,722 “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols”
Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” and
Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
“China is an increasingly open marketplace whose National Medical Products Administration recognizes and supports innovative science and medical approaches to expand the treatment options available to patients,” said Dean Petkanas, CEO of Kannalife. “This has further fueled the potential of the Chinese pharmaceutical industry, which rapidly grew to become the world’s second-biggest drug market in 2016 and registered sales of $137 billion in 2018. Looking forward, China is projected to reach half the size of America’s market by 2030 versus the current 25 percent comparison.1”
Currently, Kannalife’s leading drug candidate KLS-13019, a CBD-like molecule, is being investigated in preclinical studies for the potential treatment of neuropathic pain. Through extensive research and testing, Kannalife has identified KLS-13019 as a potent, non-opioid alternative to the frontline treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Additionally, Kannalife’s application for patent protection of its intellectual property has been accepted in the European Union (EU) and Australia. The Company is awaiting notice from Canada, Brazil and India for notice of acceptance.
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Mike Mulvihill, Senior Counsel of Padilla P: 804-334-2292 E: mike.mulvihill@padillaco.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN
The pre-clinical grant study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).
The animal model portion of the study was conducted by Sara Jane Ward, PhD, Assistant Professor of Pharmacology at LKSOM. Dr. Ward had independently begun the research focused on CBD for the potential treatment of CIPN in 2010 at LKSOM and published three papers on the subject prior to beginning the collaboration with Kannalife.
“I’m very excited about the results we have obtained with KLS-13019 to date. In our model, KLS-13019 is at least as effective as CBD to prevent neuropathic pain; however, KLS-13019 is also effective to reverse neuropathic pain as a consequence of cancer chemotherapy, whereas CBD was not effective under our test conditions. We will continue to explore the possibility that KLS-13019 could be even safer and more effective than CBD,” stated Dr. Ward.
“For KLS-13019 treatment of CIPN, significant progress has been made in identifying a molecular mechanism of protection from the complex effects of paclitaxel-induced damage of sensory nerve cells,” stated Dr. Brenneman.
The completed study could lead to a Phase 2 grant and further advances Kannalife’s belief that KLS-13019 could become a viable drug candidate, and an alternative to opioids, as a treatment for patients suffering from CIPN, and chronic pain management. CIPN is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited.1 Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.2
The global market for neuropathic pain was valued at more than $5 billion in 2015, and in 2016, CIPN accounted for more than 42 percent of market revenue. It’s estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 billion.3-4
The global opioids drug market was valued at $22.85 billion in 2017 and is expected to reach $32.6 billion by 2026, at a CAGR of 4.54% during a forecast period. Opioids are mainly used in cancer pain management and end-stage diseases in which painkilling care is required. The rising prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and increasing approval rate of abuse-deterrent formulations of opioid drugs are major driving factors of the global opioids drugs market. Extensive misuse of opioids, the growing incidence of death related to opioid overdose, and the rising number of lawsuits against opioid manufacturers are hindering the growth of the market. 5
A recently released animated video from Kannalife describes a Mechanism of Action (MOA) for KLS-13019. This video can be accessed on the Company’s website at www.kannalife.com and via Vimeo at https://vimeo.com/371214213.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Temple Health Temple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHS’s physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.
Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.
It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
References
National Center for Biotechnology Information. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Accessed at https://www.ncbi.nlm.nih.gov/books/NBK291675/.
The pre-clinical grant study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).
The animal model portion of the study was conducted by Sara Jane Ward, PhD, Assistant Professor of Pharmacology at LKSOM. Dr. Ward had independently begun the research focused on CBD for the potential treatment of CIPN in 2010 at LKSOM and published three papers on the subject prior to beginning the collaboration with Kannalife.
“I’m very excited about the results we have obtained with KLS-13019 to date. In our model, KLS-13019 is at least as effective as CBD to prevent neuropathic pain; however, KLS-13019 is also effective to reverse neuropathic pain as a consequence of cancer chemotherapy, whereas CBD was not effective under our test conditions. We will continue to explore the possibility that KLS-13019 could be even safer and more effective than CBD,” stated Dr. Ward.
“For KLS-13019 treatment of CIPN, significant progress has been made in identifying a molecular mechanism of protection from the complex effects of paclitaxel-induced damage of sensory nerve cells,” stated Dr. Brenneman.
The completed study could lead to a Phase 2 grant and further advances Kannalife’s belief that KLS-13019 could become a viable drug candidate, and an alternative to opioids, as a treatment for patients suffering from CIPN, and chronic pain management. CIPN is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited.1 Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.2
The global market for neuropathic pain was valued at more than $5 billion in 2015, and in 2016, CIPN accounted for more than 42 percent of market revenue. It’s estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 billion.3-4
The global opioids drug market was valued at $22.85 billion in 2017 and is expected to reach $32.6 billion by 2026, at a CAGR of 4.54% during a forecast period. Opioids are mainly used in cancer pain management and end-stage diseases in which painkilling care is required. The rising prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and increasing approval rate of abuse-deterrent formulations of opioid drugs are major driving factors of the global opioids drugs market. Extensive misuse of opioids, the growing incidence of death related to opioid overdose, and the rising number of lawsuits against opioid manufacturers are hindering the growth of the market. 5
A recently released animated video from Kannalife describes a Mechanism of Action (MOA) for KLS-13019. This video can be accessed on the Company’s website at www.kannalife.com and via Vimeo at https://vimeo.com/371214213.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Temple Health Temple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHS’s physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.
Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.
It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Company’s business plan, plan of operations, the viability of the Company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
References
National Center for Biotechnology Information. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Accessed at https://www.ncbi.nlm.nih.gov/books/NBK291675/.
Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Mike Mulvihill, Senior Counsel of Padilla P: 804-334-2292 E: mike.mulvihill@padillaco.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead
DOYLESTOWN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent initiatives and corporate updates.
The Company’s Chief Executive Officer, Dean Petkanas, commented: “2019 was a milestone year for Kannalife. It’s nice to see dedicated shareholders, management, employees and trusted partners and collaborators bring a small enterprising 10-year-old startup company to the cusp of expansion and commercialization efforts in 2020. With limited resources over the past decade, we have been truly blessed as we have built an impressive track record in the cannabinoid therapeutics space. We can now share the potential of our science with investors as a publicly traded company. We hope our existing and future shareholders will join us in our excitement as Kannalife continues to execute on innovative new technologies in the biotech and pharmaceutical arena.”
Highlights of the letter include:
Kannalife’s successful public listing on the OTC Venture Market under the ticker symbol “KLFE” after completing a share exchange agreement, which will enable continued research into developing disruptive cannabinoid-based therapeutics.
Results from Kannalife’s study published in the Journal of Molecular Neuroscience regarding the pharmacological comparisons between cannabidiol (CBD) and leading drug candidate KLS-13019 for the potential treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN), conducted under a research grant from the National Institute of Health (NIH) – National Institute on Drug Abuse (NIDA). This research includes potentially reducing or replacing prescription opioid use and decreasing prescription opioid abuse. Clinical trials for KLS-13019 for CIPN are targeted to begin in Q3 2021.
Expanded protection of Kannalife’s IP portfolio suite of CBD-derived new chemical entities (“NCEs”) including KLS-13019. This includes the Company’s global patent cooperation treaty (PCT) application WIPO/PCT Patent WO2015/106108A2 receiving patent approval in the U.S., Japan and Russia – along with the Company’s application for patent protection being accepted in the European Union (EU), China and Australia. The PCT patent includes several other molecules in addition to KLS-13019 and has been filed for the potential to treat diseases associated with free radical mediated stress and oxidative stress including Hepatic Encephalopathy (HE), Parkinson’s disease, Alzheimer’s, Huntington’s disease, traumatic head injury, stroke, epilepsy, neuropathic pain, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, and Epileptic Encephalopathy.
Another of Kannalife’s patent pending novel CBD-like molecules is being groomed as a consumer product to be commercialized under the trademark Atopidine™. The International Cosmetic Ingredient Nomenclature Committee assigned an International Nomenclature Cosmetic Ingredient name “Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine” (“LEA”) to Atopidine™, which has been shown in pre-clinical research to exhibit strong anti-inflammatory and antioxidant potential in addressing a number of consumer skin and personal care needs.
Commentary on Kannalife’s 2020 plans, including further research on cannabinoid therapeutics with the potential to file an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA).
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations:
Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Mike Mulvihill, Senior Counsel, Padilla P: 804-334-2292 E: mike.mulvihill@padillaco.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
DOYLESTOWN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent initiatives and corporate updates.
The Company’s Chief Executive Officer, Dean Petkanas, commented: “2019 was a milestone year for Kannalife. It’s nice to see dedicated shareholders, management, employees and trusted partners and collaborators bring a small enterprising 10-year-old startup company to the cusp of expansion and commercialization efforts in 2020. With limited resources over the past decade, we have been truly blessed as we have built an impressive track record in the cannabinoid therapeutics space. We can now share the potential of our science with investors as a publicly traded company. We hope our existing and future shareholders will join us in our excitement as Kannalife continues to execute on innovative new technologies in the biotech and pharmaceutical arena.”
Highlights of the letter include:
Kannalife’s successful public listing on the OTC Venture Market under the ticker symbol “KLFE” after completing a share exchange agreement, which will enable continued research into developing disruptive cannabinoid-based therapeutics.
Results from Kannalife’s study published in the Journal of Molecular Neuroscience regarding the pharmacological comparisons between cannabidiol (CBD) and leading drug candidate KLS-13019 for the potential treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN), conducted under a research grant from the National Institute of Health (NIH) – National Institute on Drug Abuse (NIDA). This research includes potentially reducing or replacing prescription opioid use and decreasing prescription opioid abuse. Clinical trials for KLS-13019 for CIPN are targeted to begin in Q3 2021.
Expanded protection of Kannalife’s IP portfolio suite of CBD-derived new chemical entities (“NCEs”) including KLS-13019. This includes the Company’s global patent cooperation treaty (PCT) application WIPO/PCT Patent WO2015/106108A2 receiving patent approval in the U.S., Japan and Russia – along with the Company’s application for patent protection being accepted in the European Union (EU), China and Australia. The PCT patent includes several other molecules in addition to KLS-13019 and has been filed for the potential to treat diseases associated with free radical mediated stress and oxidative stress including Hepatic Encephalopathy (HE), Parkinson’s disease, Alzheimer’s, Huntington’s disease, traumatic head injury, stroke, epilepsy, neuropathic pain, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, and Epileptic Encephalopathy.
Another of Kannalife’s patent pending novel CBD-like molecules is being groomed as a consumer product to be commercialized under the trademark Atopidine™. The International Cosmetic Ingredient Nomenclature Committee assigned an International Nomenclature Cosmetic Ingredient name “Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine” (“LEA”) to Atopidine™, which has been shown in pre-clinical research to exhibit strong anti-inflammatory and antioxidant potential in addressing a number of consumer skin and personal care needs.
Commentary on Kannalife’s 2020 plans, including further research on cannabinoid therapeutics with the potential to file an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA).
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations:
Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Mike Mulvihill, Senior Counsel, Padilla P: 804-334-2292 E: mike.mulvihill@padillaco.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife, Inc. Issues Update on Intellectual Property and Patent Estate
DOYLESTOWN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the following update on its intellectual property revolving around its global WIPO/PCT Patent WO2015/106108A2 titled “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”).
Since the filing of the PCT Patent in 2015, the Company has received patent approval in the following jurisdictions: U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” U.S. Patent 10,004,722 “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene Diols,” Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” and Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
Additionally, Kannalife’s application for patent protection of its intellectual property has been accepted in the European Union (EU), China, and Australia. The Company is awaiting notice from Canada, Brazil and India for notice of acceptance. The Company anticipates receipt of patent grants from the EU, China and Australia sometime during the first and second quarters of 2020.
“In 2015 when we filed our WIPO/PCT patent application, we chose what we believe to be the most viable pharmaceutical markets for moving our compounds into clinical trials, and for commercialization efforts, including potential collaborations and out licensing to big pharma,” stated Dean Petkanas, CEO of Kannalife.
In 2017, the pharmaceutical markets within the U.S., Canada, parts of Europe (consisting of Germany, France, Italy, UK, Spain and Greece), Brazil, China, Japan, Russia1, India2, and Australia3 made up estimated global sales4 of just over $800 billion, representing approximately 72% of all pharmaceutical sales worldwide5.
Kannalife’s intellectual property estate of the KLS Family of cannabidiol (CBD)-like molecules led by KLS-13019, as the patent states, are molecules capable of acting as neuroprotective agents and could potentially be useful for the treatment of epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).
Currently, its leading drug candidate KLS-13019, a CBD-like molecule is being investigated in pre-clinical studies for the potential treatment of neuropathic pain. Through extensive testing, Kannalife has identified a potent, non-opioid alternative to the frontline treatment of chemotherapy-induced peripheral neuropathy (CIPN).
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Mike Mulvihill, Executive Vice President of Padilla P: 804-334-2292 E: mike.mulvihill@padillaco.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
DOYLESTOWN, Pa., Jan. 22, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the following update on its intellectual property revolving around its global WIPO/PCT Patent WO2015/106108A2 titled “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”).
Since the filing of the PCT Patent in 2015, the Company has received patent approval in the following jurisdictions: U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” U.S. Patent 10,004,722 “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene Diols,” Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” and Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.”
Additionally, Kannalife’s application for patent protection of its intellectual property has been accepted in the European Union (EU), China, and Australia. The Company is awaiting notice from Canada, Brazil and India for notice of acceptance. The Company anticipates receipt of patent grants from the EU, China and Australia sometime during the first and second quarters of 2020.
“In 2015 when we filed our WIPO/PCT patent application, we chose what we believe to be the most viable pharmaceutical markets for moving our compounds into clinical trials, and for commercialization efforts, including potential collaborations and out licensing to big pharma,” stated Dean Petkanas, CEO of Kannalife.
In 2017, the pharmaceutical markets within the U.S., Canada, parts of Europe (consisting of Germany, France, Italy, UK, Spain and Greece), Brazil, China, Japan, Russia1, India2, and Australia3 made up estimated global sales4 of just over $800 billion, representing approximately 72% of all pharmaceutical sales worldwide5.
Kannalife’s intellectual property estate of the KLS Family of cannabidiol (CBD)-like molecules led by KLS-13019, as the patent states, are molecules capable of acting as neuroprotective agents and could potentially be useful for the treatment of epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).
Currently, its leading drug candidate KLS-13019, a CBD-like molecule is being investigated in pre-clinical studies for the potential treatment of neuropathic pain. Through extensive testing, Kannalife has identified a potent, non-opioid alternative to the frontline treatment of chemotherapy-induced peripheral neuropathy (CIPN).
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Andrew Hard, Chief Executive Officer of CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Mike Mulvihill, Executive Vice President of Padilla P: 804-334-2292 E: mike.mulvihill@padillaco.com
Investor Relations: Scott Gordon, Managing Director of CORE IR P: 516-222-2560 E: scottg@coreir.com www.coreir.com
Kannalife, Inc. Further Elucidates Mechanism of Action Behind KLS-13019, the Company’s Leading Drug Candidate for the Potential Treatment of Neuropathic Pain
DOYLESTOWN, Penn., Jan. 14, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid (CBD) therapeutics, announced today that it has further elucidated the mechanism of action (MOA) of its leading investigative drug candidate KLS-13019, a CBD-like molecule for the potential treatment of neuropathic pain. Through extensive pre-clinical testing and under a NIH-NIDA Phase 1 grant study, Kannalife has identified a potent, non-opioid alternative to the frontline treatment of chemotherapy-induced peripheral neuropathy (CIPN). Under the recently completed NIH-NIDA Phase 1 grant study, Kannalife’s research has shown that its leading drug candidate KLS-13019 plays an important role in the regulation of mNCX-1, an important pharmacological target in the prevention and in-part reversal of CIPN in the pre-clinical animal model. In comparison with CBD and morphine, KLS-13019 stood out as a viable drug candidate that out-performed CBD and poses as a viable alternative to the use of opioids as the frontline current standard of care for patients suffering from CIPN.
Chemotherapy-induced peripheral neuropathy is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited.1 Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.2
“There is a tremendous unmet patient need when it comes to treating neuropathic pain disorders, particularly CIPN. We believe we are on the forefront of a breakthrough in non-opioid alternatives for the treatment of chronic pain management, for which KLS-13019 represents a potential new non-addictive option with greater selectively and a wider therapeutic window of use. The target mNCX-1 is just part of the big story here. Stay tuned,” stated Dean Petkanas, CEO of Kannalife.
The global market for neuropathic pain was valued at more than $5 Billion in 2015, and in 2016, CIPN accounted for more than 42% of market revenue. It’s estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 Billion.3-4
To further bring to life the MOA of KLS-13019 as well as Kannalife’s data-driven, scientific approach to the discovery of CBD-like molecules, the Company has launched a new animated video via Vimeo at https://vimeo.com/371214213. Through its research and development efforts over the past decade, the Company has established an intellectual property estate specific to the formulation of these CBD-like compounds.
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
References
National Center for Biotechnology Information. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Accessed at https://www.ncbi.nlm.nih.gov/books/NBK291675/.
DOYLESTOWN, Penn., Jan. 14, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid (CBD) therapeutics, announced today that it has further elucidated the mechanism of action (MOA) of its leading investigative drug candidate KLS-13019, a CBD-like molecule for the potential treatment of neuropathic pain. Through extensive pre-clinical testing and under a NIH-NIDA Phase 1 grant study, Kannalife has identified a potent, non-opioid alternative to the frontline treatment of chemotherapy-induced peripheral neuropathy (CIPN). Under the recently completed NIH-NIDA Phase 1 grant study, Kannalife’s research has shown that its leading drug candidate KLS-13019 plays an important role in the regulation of mNCX-1, an important pharmacological target in the prevention and in-part reversal of CIPN in the pre-clinical animal model. In comparison with CBD and morphine, KLS-13019 stood out as a viable drug candidate that out-performed CBD and poses as a viable alternative to the use of opioids as the frontline current standard of care for patients suffering from CIPN.
Chemotherapy-induced peripheral neuropathy is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited.1 Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.2
“There is a tremendous unmet patient need when it comes to treating neuropathic pain disorders, particularly CIPN. We believe we are on the forefront of a breakthrough in non-opioid alternatives for the treatment of chronic pain management, for which KLS-13019 represents a potential new non-addictive option with greater selectively and a wider therapeutic window of use. The target mNCX-1 is just part of the big story here. Stay tuned,” stated Dean Petkanas, CEO of Kannalife.
The global market for neuropathic pain was valued at more than $5 Billion in 2015, and in 2016, CIPN accounted for more than 42% of market revenue. It’s estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 Billion.3-4
To further bring to life the MOA of KLS-13019 as well as Kannalife’s data-driven, scientific approach to the discovery of CBD-like molecules, the Company has launched a new animated video via Vimeo at https://vimeo.com/371214213. Through its research and development efforts over the past decade, the Company has established an intellectual property estate specific to the formulation of these CBD-like compounds.
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc. Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
References
National Center for Biotechnology Information. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Accessed at https://www.ncbi.nlm.nih.gov/books/NBK291675/.
Kannalife Secures New INCI Name for its Prospective Anti-Inflammatory and Antioxidant Ingredient Atopidine™
DOYLESTOWN, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the receipt of a designated International Nomenclature Cosmetic Ingredient (INCI) name for the Company’s patent-pending molecule and flagship consumer product to be sold under the trademark Atopidine™.
The International Cosmetic Ingredient Nomenclature Committee assigned the INCI name “Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine” (“LEA”) to Atopidine™, one of Kannalife’s leading novel CBD-like molecules.
“Current pre-clinical research into Atopidine™ has shown this molecule to exhibit strong anti-inflammatory and antioxidant potential applicability in addressing a number of consumer skin and personal care needs,” said Dean Petkanas, CEO of Kannalife. “We believe the INCI name assignment is one of the most important steps forward in commercialization of Atopidine™. Having an INCI name such as LEA will help advance our go-to-market strategy by providing transparency, clear product labeling, and the orderly dissemination of scientific information, to the medical community, scientists and consumers.”
INCI names are systematic names internationally recognized to identify cosmetic ingredients. They are developed by the International Nomenclature Committee (INC) and published by the Personal Care Products Council (PCPC) in the International Cosmetic Ingredient Dictionary and Handbook, available electronically as wINCI. The inclusion of any compound in the International Cosmetic Ingredient Dictionary and Handbook does not indicate that use of that substance as a cosmetic ingredient complies with the laws and regulations governing such use in the United States or any other country. Oversight for the INCI program is provided by PCPC as part of its mission to support the identification of the composition of personal care products, and publication of this information in a worldwide science-based Dictionary. The safety and suitability of ingredients intended for cosmetic products is the responsibility of the finished product manufacturer, consistent with the laws and regulations of the jurisdiction in which the product is marketed.
About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
FDA Disclaimer
The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). These statements and the drug candidates of the company are not intended to diagnose, treat or cure any disease. The efficacy of these drug candidates have not been confirmed by FDA-approved research.
DOYLESTOWN, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the receipt of a designated International Nomenclature Cosmetic Ingredient (INCI) name for the Company’s patent-pending molecule and flagship consumer product to be sold under the trademark Atopidine™.
The International Cosmetic Ingredient Nomenclature Committee assigned the INCI name “Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine” (“LEA”) to Atopidine™, one of Kannalife’s leading novel CBD-like molecules.
“Current pre-clinical research into Atopidine™ has shown this molecule to exhibit strong anti-inflammatory and antioxidant potential applicability in addressing a number of consumer skin and personal care needs,” said Dean Petkanas, CEO of Kannalife. “We believe the INCI name assignment is one of the most important steps forward in commercialization of Atopidine™. Having an INCI name such as LEA will help advance our go-to-market strategy by providing transparency, clear product labeling, and the orderly dissemination of scientific information, to the medical community, scientists and consumers.”
INCI names are systematic names internationally recognized to identify cosmetic ingredients. They are developed by the International Nomenclature Committee (INC) and published by the Personal Care Products Council (PCPC) in the International Cosmetic Ingredient Dictionary and Handbook, available electronically as wINCI. The inclusion of any compound in the International Cosmetic Ingredient Dictionary and Handbook does not indicate that use of that substance as a cosmetic ingredient complies with the laws and regulations governing such use in the United States or any other country. Oversight for the INCI program is provided by PCPC as part of its mission to support the identification of the composition of personal care products, and publication of this information in a worldwide science-based Dictionary. The safety and suitability of ingredients intended for cosmetic products is the responsibility of the finished product manufacturer, consistent with the laws and regulations of the jurisdiction in which the product is marketed.
About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
FDA Disclaimer
The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). These statements and the drug candidates of the company are not intended to diagnose, treat or cure any disease. The efficacy of these drug candidates have not been confirmed by FDA-approved research.
Cannabidiol, or CBD, is one of several compounds extracted from the cannabis (marijuana) plant. In recent years, CBD has become enormously popular, and its market is believed to be hundreds of millions of dollars. Believers and users of CBD extoll its benefits for inflammation, muscle soreness, pain, anxiety and a whole host of other things, including cancer.
It is, however, very understudied. There is little if any information on appropriate dosing, let alone the efficacy or safety of CBD.
Recently, the U.S. Food and Drug Administration (FDA) issued warning letters to 15 companies for illegally selling products that contain CBD in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). It also published a revised Consumer Update describing its safety concerns over CBD products in general. One of the conclusions of the report is that the agency “cannot conclude that CBD is generally recognized as safe (GRAS) among qualified experts for its use in human or animal food.”
Douglas Brenneman, who spent much of his career at the National Institute of Child Health and Human Development at the National Institutes of Health (NIH) and who was a senior research fellow at Johnson & Johnson, spoke with BioSpace about CBD and his scientific advisory work for Kannalife, which is developing CBD analogs for clinical use. Brenneman is also founder and chief scientific officer of Advanced Neural Dynamics.
In terms of CBD, Brenneman notes, “That whole area has changed dramatically in the last year. The real game-changer was when Epidiolex went on the market.”
In November 2018, GW Pharmaceuticals, with offices in London, UK and Carlsbad, California, announced the FDA had approved Epidiolex (cannabidiol) for seizures associated with Lennox-Gastaut syndrome (LGS) or Draven syndrome, which are severe forms of childhood epilepsy. The drug, a form of cannabidiol, is marketed in the U.S. by a GW subsidiary, Greenwich Biosciences.
Brenneman notes that people have had a tendency to anecdotally claim that CBD was safe, “but when they actually went and tested it in a clinical trial, they found a number of toxicities that were of significant concern. The number one concern is liver toxicity. In terms of Epidiolex, what they found was that almost 15% of the patients had elevated levels of serum transaminases. There were several enzymes that were elevated that were indicative of liver toxicity. That was one red flag that came up.”
Another was the danger of Epidiolex and CBD in developing organisms, which is another way of saying fetuses.
“One of the hats I wear is a developmental biologist. They found no safe dose has been found for any organism that is in the developing system. In other words, anyone who is pregnant or even thinking of getting pregnant should be nowhere close to this drug,” Brenneman said. “There is no safe dose of CBD for someone who is pregnant in terms of fetal exposure.”
He says that when you’re discussing drugs, you’re talking about risk-benefit ratio. “And when you’re talking about these desperately ill children who had epilepsy, the FDA decided it’s probably okay because these kids were having huge numbers of seizures a day and Epidiolex really did help. It was a very effective anti-convulsant in these children, despite the fact there were these concerns about liver toxicity.”
One hopeful aspect of this was that when they stopped taking the drug, the liver symptoms went away, so there was a clear cause and effect, which was also dose dependent—the higher the doses, the higher the liver toxicity.
Moving on to a little broader understanding of cannabinoids, Brenneman said, “If you’re taking these drugs, you’d better watch your liver enzymes. You’d better watch out. Not everyone responds that way, a majority don’t, but it’s one of the confounding aspects of giving cannabinoids. We are not all created equal. We vary the number of receptors and characteristics of how people respond to cannabinoids.”
Which brings us to Kannalife. The company was founded in 2010 and all of its patents are co-invented by Brenneman. Kannalife is developing proprietary CBD and CBD-like molecules for neurodegenerative disorders, including chemotherapy-induced peripheral neuropathy (CIPN). This is a chronic nerve pain caused by the toxic aspects of chemotherapy drugs. It is also working on other neurodegenerative disorders that can potentially be treated with CBD analogs.
The lead compound is KLS-13019.
“One of the confounding aspects of CBD is that it interacts with many, many targets, at least a dozen,” Brenneman said. “And at least four of them are in areas we’re interested in, which is neuroprotection. The compounds we’re developing protect the nerve cells from clinically relevant toxins.”
In developing KLS-13019, the compound lost its anti-convulsant properties, but dramatically increased the pharmacological focus in the nervous system.
Brenneman said, “Now we have a potent neuroprotective molecule. We’re getting some understanding of properties it can elicit that CBD cannot.”
So far the drug is been tested in culture and animals, treating the nerve damage that elicits nerve pain from use of a chemotherapeutic called paclitaxel. Much of the toxicology work has been conducted by Sara Jane Ward at Temple University.
Brenneman presented data on KLS-13019 in June 2019 at the 29th Annual International Cannabinoid Research Society Symposium on Cannabinoids. The research was in collaboration with Ward’s work at Temple and funded by a grant from the National Institute on Drug Abuse.
“Interestingly enough, you have to realize that neuropathic pain has several components, several phases. One of the initial ones is just a reaction to the drug itself, which is basically an oxidative stressor,” Brenneman said. “It starts damaging the neurons. This happens within hours. It’s this initial phase we’re trying to protect from. CBD and KLS-13019 both do a great job there. But this is only the initial phase when we’re trying to protect the nerve cells.”
He adds that you need hundreds of times more CBD than KLS-13109 for the same effect, but they both work.
But the real differentiator, Brenneman said, is what they’re currently working on. It’s an actual reversal of neuropathic pain. And this appears to be a major difference between CBD and KLS-13109, at least in animal models.
“It’s night and day. CBD has no effect in terms of reversing the neuropathic pain,” Brenneman said. “But our compound, at reasonably low doses, is able to completely reverse the neuropathic pain in these animals.”
One of their control substances is morphine, which is used to ameliorate neuropathic pain associated with chemotherapy. Brenneman points out that morphine does the job quite well, but because of the addictive quality, and the current opioid epidemic, there are numerous reasons to not use morphine in this context. However, KLS-13109 has no effect on the reward pathways in the brain and doesn’t interact with any opiate receptor. “Here we have a clear difference between CBD and our compound, which is what we’re excited about.”
At this time, Kannalife is looking to complete its animal toxicology studies in the next year and then hopes to get into the clinic sometime in 2021. “We have a lot of boxes to check for the FDA,” he said.
Although Kannalife is currently focused on neuropathic pain, KLS-13109 and potentially other analogs under development, may be effective in other areas, particularly when you consider the non-opiate qualities and neuroprotective effects.
“There’s a whole other array of neurodegenerative disease we’re potentially interested in and looking at,” Brenneman said. “It’s not just a matter of differentiating ourselves from CBD, but also expanding our therapeutic interest to see what this compound can do.”
Cannabidiol, or CBD, is one of several compounds extracted from the cannabis (marijuana) plant. In recent years, CBD has become enormously popular, and its market is believed to be hundreds of millions of dollars. Believers and users of CBD extoll its benefits for inflammation, muscle soreness, pain, anxiety and a whole host of other things, including cancer.
It is, however, very understudied. There is little if any information on appropriate dosing, let alone the efficacy or safety of CBD.
Recently, the U.S. Food and Drug Administration (FDA) issued warning letters to 15 companies for illegally selling products that contain CBD in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). It also published a revised Consumer Update describing its safety concerns over CBD products in general. One of the conclusions of the report is that the agency “cannot conclude that CBD is generally recognized as safe (GRAS) among qualified experts for its use in human or animal food.”
Douglas Brenneman, who spent much of his career at the National Institute of Child Health and Human Development at the National Institutes of Health (NIH) and who was a senior research fellow at Johnson & Johnson, spoke with BioSpace about CBD and his scientific advisory work for Kannalife, which is developing CBD analogs for clinical use. Brenneman is also founder and chief scientific officer of Advanced Neural Dynamics.
In terms of CBD, Brenneman notes, “That whole area has changed dramatically in the last year. The real game-changer was when Epidiolex went on the market.”
In November 2018, GW Pharmaceuticals, with offices in London, UK and Carlsbad, California, announced the FDA had approved Epidiolex (cannabidiol) for seizures associated with Lennox-Gastaut syndrome (LGS) or Draven syndrome, which are severe forms of childhood epilepsy. The drug, a form of cannabidiol, is marketed in the U.S. by a GW subsidiary, Greenwich Biosciences.
Brenneman notes that people have had a tendency to anecdotally claim that CBD was safe, “but when they actually went and tested it in a clinical trial, they found a number of toxicities that were of significant concern. The number one concern is liver toxicity. In terms of Epidiolex, what they found was that almost 15% of the patients had elevated levels of serum transaminases. There were several enzymes that were elevated that were indicative of liver toxicity. That was one red flag that came up.”
Another was the danger of Epidiolex and CBD in developing organisms, which is another way of saying fetuses.
“One of the hats I wear is a developmental biologist. They found no safe dose has been found for any organism that is in the developing system. In other words, anyone who is pregnant or even thinking of getting pregnant should be nowhere close to this drug,” Brenneman said. “There is no safe dose of CBD for someone who is pregnant in terms of fetal exposure.”
He says that when you’re discussing drugs, you’re talking about risk-benefit ratio. “And when you’re talking about these desperately ill children who had epilepsy, the FDA decided it’s probably okay because these kids were having huge numbers of seizures a day and Epidiolex really did help. It was a very effective anti-convulsant in these children, despite the fact there were these concerns about liver toxicity.”
One hopeful aspect of this was that when they stopped taking the drug, the liver symptoms went away, so there was a clear cause and effect, which was also dose dependent—the higher the doses, the higher the liver toxicity.
Moving on to a little broader understanding of cannabinoids, Brenneman said, “If you’re taking these drugs, you’d better watch your liver enzymes. You’d better watch out. Not everyone responds that way, a majority don’t, but it’s one of the confounding aspects of giving cannabinoids. We are not all created equal. We vary the number of receptors and characteristics of how people respond to cannabinoids.”
Which brings us to Kannalife. The company was founded in 2010 and all of its patents are co-invented by Brenneman. Kannalife is developing proprietary CBD and CBD-like molecules for neurodegenerative disorders, including chemotherapy-induced peripheral neuropathy (CIPN). This is a chronic nerve pain caused by the toxic aspects of chemotherapy drugs. It is also working on other neurodegenerative disorders that can potentially be treated with CBD analogs.
The lead compound is KLS-13019.
“One of the confounding aspects of CBD is that it interacts with many, many targets, at least a dozen,” Brenneman said. “And at least four of them are in areas we’re interested in, which is neuroprotection. The compounds we’re developing protect the nerve cells from clinically relevant toxins.”
In developing KLS-13019, the compound lost its anti-convulsant properties, but dramatically increased the pharmacological focus in the nervous system.
Brenneman said, “Now we have a potent neuroprotective molecule. We’re getting some understanding of properties it can elicit that CBD cannot.”
So far the drug is been tested in culture and animals, treating the nerve damage that elicits nerve pain from use of a chemotherapeutic called paclitaxel. Much of the toxicology work has been conducted by Sara Jane Ward at Temple University.
Brenneman presented data on KLS-13019 in June 2019 at the 29th Annual International Cannabinoid Research Society Symposium on Cannabinoids. The research was in collaboration with Ward’s work at Temple and funded by a grant from the National Institute on Drug Abuse.
“Interestingly enough, you have to realize that neuropathic pain has several components, several phases. One of the initial ones is just a reaction to the drug itself, which is basically an oxidative stressor,” Brenneman said. “It starts damaging the neurons. This happens within hours. It’s this initial phase we’re trying to protect from. CBD and KLS-13019 both do a great job there. But this is only the initial phase when we’re trying to protect the nerve cells.”
He adds that you need hundreds of times more CBD than KLS-13109 for the same effect, but they both work.
But the real differentiator, Brenneman said, is what they’re currently working on. It’s an actual reversal of neuropathic pain. And this appears to be a major difference between CBD and KLS-13109, at least in animal models.
“It’s night and day. CBD has no effect in terms of reversing the neuropathic pain,” Brenneman said. “But our compound, at reasonably low doses, is able to completely reverse the neuropathic pain in these animals.”
One of their control substances is morphine, which is used to ameliorate neuropathic pain associated with chemotherapy. Brenneman points out that morphine does the job quite well, but because of the addictive quality, and the current opioid epidemic, there are numerous reasons to not use morphine in this context. However, KLS-13109 has no effect on the reward pathways in the brain and doesn’t interact with any opiate receptor. “Here we have a clear difference between CBD and our compound, which is what we’re excited about.”
At this time, Kannalife is looking to complete its animal toxicology studies in the next year and then hopes to get into the clinic sometime in 2021. “We have a lot of boxes to check for the FDA,” he said.
Although Kannalife is currently focused on neuropathic pain, KLS-13109 and potentially other analogs under development, may be effective in other areas, particularly when you consider the non-opiate qualities and neuroprotective effects.
“There’s a whole other array of neurodegenerative disease we’re potentially interested in and looking at,” Brenneman said. “It’s not just a matter of differentiating ourselves from CBD, but also expanding our therapeutic interest to see what this compound can do.”
Kannalife, Inc. Announces Filing of U.S. Patent 62/934,861 – Functionalized 1, 3 Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders
DOYLESTOWN, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the filing of a new U.S. Patent for its proprietary and novel CBD-like molecules to treat radiation dermatitis (RD) and other skin disorders.
The major side effect of RD is skin tissue damage also known as radiodermatitis which occurs in 95% of cancer patients receiving radiation therapy (RT). While acute inflammation is observed within hours of RT, this painful and common side effect develops over weeks and its severity with time progresses to erythema, dry or wet desquamation or ulceration. Currently, no single agent has been shown to completely alleviate the radiation dermatitis side effect. Current therapies that focus on the symptoms include corticosteroid cream, antibiotics, zinc and amifostine. Because of the widespread incidence and the paucity of completely effective therapies, there is an urgent need for new and effective therapies, particularly those employing small molecules that are directed on regulating free radicals and decreasing the concentration of mediators of inflammation which are largely cytokines.
A December 2017 report by Transparency Market Research projects the radiodermatitis market to reach $420 million by 2024.
“We are currently in the midst of and performing pre-clinical research on our lead compound covered under our patent filing. We believe we have a solid candidate to bring forth to bridge the gap from current therapies that focus on symptoms to a therapeutic agent and more readily alleviate the RT side effect,” said Dean Petkanas, CEO of Kannalife. “Again, our early research efforts into the limitations and potential for CBD has brought us to creating a new class of patented CBD-like compounds such as KLS-13019. We believe as is the case in KLS-13019, the new compounds now subject to our patent 62/934,861 patent filing have significant advantages to CBD in treating oxidative stress-related diseases.”
About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
FDA Disclaimer
The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). These statements and the drug candidates of the company are not intended to diagnose, treat or cure any disease. The efficacy of these drug candidates have not been confirmed by FDA-approved research.
DOYLESTOWN, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the filing of a new U.S. Patent for its proprietary and novel CBD-like molecules to treat radiation dermatitis (RD) and other skin disorders.
The major side effect of RD is skin tissue damage also known as radiodermatitis which occurs in 95% of cancer patients receiving radiation therapy (RT). While acute inflammation is observed within hours of RT, this painful and common side effect develops over weeks and its severity with time progresses to erythema, dry or wet desquamation or ulceration. Currently, no single agent has been shown to completely alleviate the radiation dermatitis side effect. Current therapies that focus on the symptoms include corticosteroid cream, antibiotics, zinc and amifostine. Because of the widespread incidence and the paucity of completely effective therapies, there is an urgent need for new and effective therapies, particularly those employing small molecules that are directed on regulating free radicals and decreasing the concentration of mediators of inflammation which are largely cytokines.
A December 2017 report by Transparency Market Research projects the radiodermatitis market to reach $420 million by 2024.
“We are currently in the midst of and performing pre-clinical research on our lead compound covered under our patent filing. We believe we have a solid candidate to bring forth to bridge the gap from current therapies that focus on symptoms to a therapeutic agent and more readily alleviate the RT side effect,” said Dean Petkanas, CEO of Kannalife. “Again, our early research efforts into the limitations and potential for CBD has brought us to creating a new class of patented CBD-like compounds such as KLS-13019. We believe as is the case in KLS-13019, the new compounds now subject to our patent 62/934,861 patent filing have significant advantages to CBD in treating oxidative stress-related diseases.”
About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
FDA Disclaimer
The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). These statements and the drug candidates of the company are not intended to diagnose, treat or cure any disease. The efficacy of these drug candidates have not been confirmed by FDA-approved research.
Kannalife, Inc. Commences Trading on OTCQB Under Ticker Symbol “KLFE”
DOYLESTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, brings proven cannabinoid R&D to the public by officially commencing trading on the OTC Markets under the ticker symbol “KLFE.” The Company previously had a registration statement on Form S-1 go effective with the Securities and Exchange Commission on August 12, 2019, covering the secondary sale of securities by certain stockholders of the Company.
Kannalife has developed its own patented intellectual property estate of molecules led by KLS-13019, the company’s novel CBD-like molecule to treat neurodegenerative, chronic pain management and oxidative stress-related diseases. Kannalife has made significant improvements in the chemistry and efficacy of their new CBD-like molecules. The Company was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy” and U.S. Patent #10004722, “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols.”
“For the past 10 years Kannalife has dedicated itself to the clinical development of novel cannabinoid therapeutics as ethical pharmaceuticals. We started out by extensively researching the pharmaceutical potential of cannabidiol (CBD). But unlike many others who chose to take shortcuts and simply dump CBD into the market in an unregulated manner, we took the accountable route of understanding the pharmacokinetic and pharmacodynamic limitations of CBD,” said Dean Petkanas, CEO of Kannalife. “Through our pioneering and responsible life sciences efforts, we embarked upon a data driven, scientific approach to advance the potential of CBD. We did this by creating a new class of patented CBD-like compounds that pre-clinical studies show are up to 200 times more potent, 10 times more bioavailable, 5 times safer and 1,000 times more effective (therapeutic index) than CBD. We believe that these compounds will eventually be considered “CBD 2.0.” Pre-clinical studies have indicated that they may address some of generic CBD’s limitations but are also narrowly and specifically targeted with well understood mechanisms of action for neurodegeneration, chronic pain management and oxidative stress-related diseases.”
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
FDA Disclaimer
The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). These statements and the drug candidates of the company are not intended to diagnose, treat or cure any disease. The efficacy of these drug candidates have not been confirmed by FDA-approved research.
DOYLESTOWN, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, brings proven cannabinoid R&D to the public by officially commencing trading on the OTC Markets under the ticker symbol “KLFE.” The Company previously had a registration statement on Form S-1 go effective with the Securities and Exchange Commission on August 12, 2019, covering the secondary sale of securities by certain stockholders of the Company.
Kannalife has developed its own patented intellectual property estate of molecules led by KLS-13019, the company’s novel CBD-like molecule to treat neurodegenerative, chronic pain management and oxidative stress-related diseases. Kannalife has made significant improvements in the chemistry and efficacy of their new CBD-like molecules. The Company was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy” and U.S. Patent #10004722, “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols.”
“For the past 10 years Kannalife has dedicated itself to the clinical development of novel cannabinoid therapeutics as ethical pharmaceuticals. We started out by extensively researching the pharmaceutical potential of cannabidiol (CBD). But unlike many others who chose to take shortcuts and simply dump CBD into the market in an unregulated manner, we took the accountable route of understanding the pharmacokinetic and pharmacodynamic limitations of CBD,” said Dean Petkanas, CEO of Kannalife. “Through our pioneering and responsible life sciences efforts, we embarked upon a data driven, scientific approach to advance the potential of CBD. We did this by creating a new class of patented CBD-like compounds that pre-clinical studies show are up to 200 times more potent, 10 times more bioavailable, 5 times safer and 1,000 times more effective (therapeutic index) than CBD. We believe that these compounds will eventually be considered “CBD 2.0.” Pre-clinical studies have indicated that they may address some of generic CBD’s limitations but are also narrowly and specifically targeted with well understood mechanisms of action for neurodegeneration, chronic pain management and oxidative stress-related diseases.”
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
Forward-Looking Statements This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the company’s business plan, plan of operations, the viability of the company’s drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
FDA Disclaimer
The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). These statements and the drug candidates of the company are not intended to diagnose, treat or cure any disease. The efficacy of these drug candidates have not been confirmed by FDA-approved research.
Kannalife, Inc. to Present Breakthrough CIPN Study Findings on the Comparison of KLS-13019 to CBD at 29th Annual International Cannabinoid Research Society Conference
DOYLESTOWN, Pa., June 27, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (OTC: KLFE) (“Kannalife” or “the Company”), a biopharmaceutical company focused on the research, development and discovery of natural and novel biomimetic cannabinoid therapeutic agents, announced today that Douglas Brenneman, PhD, will present the Company’s recent research findings at the 29th Annual International Cannabinoid Research Society Symposium on the Cannabinoids in Bethesda, Md., on July 2.
Dr. Brenneman, slated to begin his presentation at 11:15 am EST on July 2, will discuss the Company’s research findings recently published in the Journal of Molecular Neuroscience (JOMN). The research published in the JOMN describes, in detail, the siRNA knockdown and mechanism of action for both KLS-13019 and cannabidiol (CBD) in the potential treatment of chemotherapy-induced peripheral neuropathy (CIPN).
“With up to 30 to 40 percent of patients undergoing chemotherapy afflicted with CIPN, there is a compelling case to be made to continue research on how to provide them with a reliable treatment option that does not involve opiates,” Brenneman said.
Kannalife’s research into neuropathic pain was performed in collaboration with the Lewis Katz School of Medicine at Temple University (LKSOM) and funded by a grant from the National Institute on Drug Abuse. The study performed compares Kannalife’s lead cannabidiol-derived compound KLS-13019 to pure cannabidiol (CBD) on the sodium-calcium exchanger (mNCX-1) target and its effects on the mitochondrial function, a major component in cellular respiration, energy, reactive oxygen species (ROS) and intracellular calcium mobilization, which play a role in neuropathic pain and inflammatory pain. Sara Jane Ward, PhD, Assistant Professor of Pharmacology at LKSOM, independently began the research focused on CBD for the potential treatment of CIPN in 2010 at LKSOM and published three papers on the subject prior to beginning the collaboration with Kannalife.
The study advances Kannalife’s belief that KLS-13019 could become a viable target drug candidate, and alternative to opioids, as a treatment for patients suffering from CIPN.
“We are dedicated to finding innovative treatment options for those suffering from a range of diseases,” Kannalife CCO Thoma Kikis said. “Kannalife is proud to present our research findings at the prestigious 29th Annual ICRS Symposium on the Cannabinoids.”
The International Cannabinoid Research Society is a non-political, non-religious organization dedicated to scientific research in all fields of the cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system to studies of the abuse potential of recreational cannabis. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research.
About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This release contains statements about expected future events, the viability of Kannalife’s drug candidates and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Kannalife does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer, CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
DOYLESTOWN, Pa., June 27, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (OTC: KLFE) (“Kannalife” or “the Company”), a biopharmaceutical company focused on the research, development and discovery of natural and novel biomimetic cannabinoid therapeutic agents, announced today that Douglas Brenneman, PhD, will present the Company’s recent research findings at the 29th Annual International Cannabinoid Research Society Symposium on the Cannabinoids in Bethesda, Md., on July 2.
Dr. Brenneman, slated to begin his presentation at 11:15 am EST on July 2, will discuss the Company’s research findings recently published in the Journal of Molecular Neuroscience (JOMN). The research published in the JOMN describes, in detail, the siRNA knockdown and mechanism of action for both KLS-13019 and cannabidiol (CBD) in the potential treatment of chemotherapy-induced peripheral neuropathy (CIPN).
“With up to 30 to 40 percent of patients undergoing chemotherapy afflicted with CIPN, there is a compelling case to be made to continue research on how to provide them with a reliable treatment option that does not involve opiates,” Brenneman said.
Kannalife’s research into neuropathic pain was performed in collaboration with the Lewis Katz School of Medicine at Temple University (LKSOM) and funded by a grant from the National Institute on Drug Abuse. The study performed compares Kannalife’s lead cannabidiol-derived compound KLS-13019 to pure cannabidiol (CBD) on the sodium-calcium exchanger (mNCX-1) target and its effects on the mitochondrial function, a major component in cellular respiration, energy, reactive oxygen species (ROS) and intracellular calcium mobilization, which play a role in neuropathic pain and inflammatory pain. Sara Jane Ward, PhD, Assistant Professor of Pharmacology at LKSOM, independently began the research focused on CBD for the potential treatment of CIPN in 2010 at LKSOM and published three papers on the subject prior to beginning the collaboration with Kannalife.
The study advances Kannalife’s belief that KLS-13019 could become a viable target drug candidate, and alternative to opioids, as a treatment for patients suffering from CIPN.
“We are dedicated to finding innovative treatment options for those suffering from a range of diseases,” Kannalife CCO Thoma Kikis said. “Kannalife is proud to present our research findings at the prestigious 29th Annual ICRS Symposium on the Cannabinoids.”
The International Cannabinoid Research Society is a non-political, non-religious organization dedicated to scientific research in all fields of the cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system to studies of the abuse potential of recreational cannabis. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research.
About Kannalife, Inc.
Kannalife, Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This release contains statements about expected future events, the viability of Kannalife’s drug candidates and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Kannalife does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer, CMW Media P: 888-829-0070 E: andrew.hard@cmwmedia.com
Kannalife Inc. Publishes New Research on Chemotherapy-Induced Peripheral Neuropathy
Novel Mechanism of Action Studied Comparing Cannabidiol (CBD) and Kannalife’s Proprietary CBD-like Molecule Published in the Journal of Molecular Neuroscience
DOYLESTOWN, Pa., May 21, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (OTC:KLFE), Kannalife (“Kannalife” or “the Company”), a biopharmaceutical company leading innovation in research, development and discovery of natural and novel biomimetic cannabinoid therapeutic agents, announces today the publication of its research findings around Chemotherapy-Induced Peripheral Neuropathy (CIPN) in the Journal of Molecular Neuroscience.
Chemotherapy-induced peripheral neuropathy is defined as a progressive, enduring and often irreversible condition featuring pain, numbness, tingling and sensitivity to cold in the hands and feet (sometimes progressing to the arms and legs) that afflicts between 30-40 percent of patients undergoing chemotherapy.
“There is an unmet medical need in neuropathic pain overall,” states Douglas Brenneman, PhD and scientist at Kannalife. “In this particular case, it was not a classic neurodegenerative disease like Alzheimer’s or Parkinson’s disease. It is a neurological problem associated with a drug. There’s a huge need for symptomatic relief for CIPN specifically because so many people are affected but we’re looking for ways to treat a neurological problem.”
“We believe our research and development efforts will continue to push the envelope in advancing scientific discovery in the field of cannabinoid therapeutics,” states Thoma Kikis, CCO of Kannalife. “We are extremely fortunate to have a great team of scientists working together and leading the effort to bring forth a new solution in the treatment of CIPN.”
The Company worked on this research under a grant from the National Institute on Drug Abuse it received in 2017. The grant allows for research into the development of KLS-13019 for chemotherapy-induced peripheral neuropathy and drug dependence. According to the grant, the Company is researching significant advancements in identifying the specific mechanisms that induce CIPN, application of that knowledge to design novel treatment strategies for neuropathic pain, and applying those treatment strategies to reduce or replace prescription opioid use and decrease prescription opioid abuse. Clinical trials for KLS-13019 as a therapeutic for CIPN is targeted to begin in Q2 2020.
A multimedia, interactive version of this release that includes images and other resources is available.
About Kannalife Inc. Kannalife Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Kannalife does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer, CMW Media P: 888-829-0070 E:andrew.hard@cmwmedia.com
Novel Mechanism of Action Studied Comparing Cannabidiol (CBD) and Kannalife’s Proprietary CBD-like Molecule Published in the Journal of Molecular Neuroscience
DOYLESTOWN, Pa., May 21, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (OTC:KLFE), Kannalife (“Kannalife” or “the Company”), a biopharmaceutical company leading innovation in research, development and discovery of natural and novel biomimetic cannabinoid therapeutic agents, announces today the publication of its research findings around Chemotherapy-Induced Peripheral Neuropathy (CIPN) in the Journal of Molecular Neuroscience.
Chemotherapy-induced peripheral neuropathy is defined as a progressive, enduring and often irreversible condition featuring pain, numbness, tingling and sensitivity to cold in the hands and feet (sometimes progressing to the arms and legs) that afflicts between 30-40 percent of patients undergoing chemotherapy.
“There is an unmet medical need in neuropathic pain overall,” states Douglas Brenneman, PhD and scientist at Kannalife. “In this particular case, it was not a classic neurodegenerative disease like Alzheimer’s or Parkinson’s disease. It is a neurological problem associated with a drug. There’s a huge need for symptomatic relief for CIPN specifically because so many people are affected but we’re looking for ways to treat a neurological problem.”
“We believe our research and development efforts will continue to push the envelope in advancing scientific discovery in the field of cannabinoid therapeutics,” states Thoma Kikis, CCO of Kannalife. “We are extremely fortunate to have a great team of scientists working together and leading the effort to bring forth a new solution in the treatment of CIPN.”
The Company worked on this research under a grant from the National Institute on Drug Abuse it received in 2017. The grant allows for research into the development of KLS-13019 for chemotherapy-induced peripheral neuropathy and drug dependence. According to the grant, the Company is researching significant advancements in identifying the specific mechanisms that induce CIPN, application of that knowledge to design novel treatment strategies for neuropathic pain, and applying those treatment strategies to reduce or replace prescription opioid use and decrease prescription opioid abuse. Clinical trials for KLS-13019 as a therapeutic for CIPN is targeted to begin in Q2 2020.
A multimedia, interactive version of this release that includes images and other resources is available.
About Kannalife Inc. Kannalife Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company’s family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company’s Twitter page at @Kannalife.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Kannalife does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations: Andrew Hard, Chief Executive Officer, CMW Media P: 888-829-0070 E:andrew.hard@cmwmedia.com
Kannalife Spokesman former NFL kicker Nick Lowery on Head Injuries, CBD Treatment
Kannalife Spokesman Nick Lowery Wins 2018 CNBC Stock Draft
DOYLESTOWN, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce and congratulate the Company’s spokesperson – former NFL and Kansas City Chiefs Hall of Famer – Nick Lowery for winning the 2018 CNBC Stock Draft with his picks of Amazon (Nasdaq:AMZN), Goldman Sachs (NYSE:GS) and AMD (Nasdaq:AMD).
Nick’s incredible acumen for business played itself out in 2018 as he was awarded top honors in the annual CNBC Stock Draft. We also extend our appreciation and recognition for his accomplishments and humanitarian efforts. Nick was just honored with the 2019 Steinberg DeNicola Humanitarian Award during Superbowl LIII week in Atlanta, and will be the honoree at the American Cancer Society’s 58th Annual Evening of Hope on February 16th, 2019 in Phoenix, Arizona.
Dean Petkanas, CEO of Kannalife, stated, “It is an honor and a privilege to have Nick Lowery as a part of our team at Kannalife in support of our efforts to combat neurodegenerative and oxidative stress related diseases in the emerging field of cannabinoid therapeutics.”
About Kannalife, Inc. – A Phyto-Medical Company™
Kannalife, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy (“HE”), chronic traumatic encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy (“CIPN”). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P: 888-829-0070 andrew.hard@cmwmedia.com www.cmwmedia.com
DOYLESTOWN, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce and congratulate the Company’s spokesperson – former NFL and Kansas City Chiefs Hall of Famer – Nick Lowery for winning the 2018 CNBC Stock Draft with his picks of Amazon (Nasdaq:AMZN), Goldman Sachs (NYSE:GS) and AMD (Nasdaq:AMD).
Nick’s incredible acumen for business played itself out in 2018 as he was awarded top honors in the annual CNBC Stock Draft. We also extend our appreciation and recognition for his accomplishments and humanitarian efforts. Nick was just honored with the 2019 Steinberg DeNicola Humanitarian Award during Superbowl LIII week in Atlanta, and will be the honoree at the American Cancer Society’s 58th Annual Evening of Hope on February 16th, 2019 in Phoenix, Arizona.
Dean Petkanas, CEO of Kannalife, stated, “It is an honor and a privilege to have Nick Lowery as a part of our team at Kannalife in support of our efforts to combat neurodegenerative and oxidative stress related diseases in the emerging field of cannabinoid therapeutics.”
About Kannalife, Inc. – A Phyto-Medical Company™
Kannalife, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy (“HE”), chronic traumatic encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy (“CIPN”). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P: 888-829-0070 andrew.hard@cmwmedia.com www.cmwmedia.com
Kannalife Announces Completion of Name Change, Ticker Symbol Change
Doylestown, PA – January 16, 2019 – Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce that the Company’s name change from TYG Solutions Corp. to Kannalife, Inc. and the change of ticker symbol to “KLFE” has been reviewed and processed by the Financial Industry Regulatory Authority (FINRA).
The name and ticker symbol change is effective at the opening of trading tomorrow, January 17, 2019.
Dean Petkanas, CEO of Kannalife, stated “We are excited that the corporate actions have been processed by FINRA. This is one of the first steps in the growth of our status as a public company as we continue our research and development into developing disruptive cannabinoid-based therapeutics for neurodegenerative and oxidative stress-related diseases.”
About Kannalife, Inc. – A Phyto-Medical Company™
Kannalife, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy (“HE”), chronic traumatic encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy (CIPN). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
###
CONTACT:
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P: 888-829-0070 andrew.hard@cmwmedia.com www.cmwmedia.com
Source: Kannalife, Inc.
Doylestown, PA – January 16, 2019 – Kannalife, Inc. (“Kannalife”) (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, is pleased to announce that the Company’s name change from TYG Solutions Corp. to Kannalife, Inc. and the change of ticker symbol to “KLFE” has been reviewed and processed by the Financial Industry Regulatory Authority (FINRA).
The name and ticker symbol change is effective at the opening of trading tomorrow, January 17, 2019.
Dean Petkanas, CEO of Kannalife, stated “We are excited that the corporate actions have been processed by FINRA. This is one of the first steps in the growth of our status as a public company as we continue our research and development into developing disruptive cannabinoid-based therapeutics for neurodegenerative and oxidative stress-related diseases.”
About Kannalife, Inc. – A Phyto-Medical Company™
Kannalife, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy (“HE”), chronic traumatic encephalopathy (“CTE”) and Chemotherapy Induced Peripheral Neuropathy (CIPN). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
###
CONTACT:
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P: 888-829-0070 andrew.hard@cmwmedia.com www.cmwmedia.com
Source: Kannalife, Inc.
Kannalife’s Nick Lowery is still motivated by memories of teammate Mike Webster
Gene Collier: How Mike Webster memories still motivate ex-Chief Nick Lowery
With four weeks remaining in yet another imponderable NFL season, it’s impossible to say whether the Steelers or the Baltimore Ravens will win an AFC North race that is, as the great broadcaster Red Barber liked to say, “tighter than a new pair of shoes on a rainy day.”
Moreover, it’s impossible to know who among the conference’s top contemporary swaggerers — Kansas City, New England, Houston or those Steelers-slaying fresh princes of BelAir, the Los Angeles Chargers — will erect the greatest impediment to Pittsburgh’s perpetual Super Bowl fixation.
But there is, in all of this, one absolute certainty.
Before the playoffs begin, someone will remind the Chiefs, who have the best record in the AFC at 10-2, that they haven’t won a home playoff game in 25 years.
It may as well be Nick Lowery, who long before becoming the first pro athlete to graduate from Harvard’s JFK School of Government with that master’s in public administration, kicked the overtime field goal that beat the Steelers, 27-24, on that bone cold day in Missouri nearly a quarter century ago. It was Jan. 8, 1994.
“I remember thinking, ‘This is the biggest kick of my life,’ and just saying, ‘Trust your training, just trust your training, keep your [darn] head down,’ ” Lowery remembered one day this past week. “And I will never forget, because that was the last kick I ever had in Arrowhead Stadium in my career as a Chief. I’ve got a picture of that in my kitchen, of 80,000 people in red like a huge human wave standing up, and all my teammates running on.”
A three-time Pro Bowler and the leading scorer in Chiefs history, Lowery played for the Patriots and the Jets as well in an 18-year-career that ended in 1996, but he’s still got killer Steelers stories.
“Pro Bowl, 1982, surrealistically beautiful palm trees, beautiful Hawaiian ladies, and there’s Jack Lambert,” this one begins. “And Jack, every night at about 8:30, was going to a country music bar for a couple of beers and sometimes I’d join him, and around the second or third beer they’d challenge him to come up on stage — the band would — and he’d get up and sing pretty well.
“So we had a little bit of a friendship, and we had an amazing team, Don Shula was the coach and Earl Campbell was there and John Hannah, Steve Largent, Dan Fouts. So the game comes and it’s 13-13 late and we’re driving down the field, a game-winning field goal situation, and Lambert comes up to me on the sideline with this toothless smile and says, ‘Rookie (and I wasn’t a rookie), we make $5,000 if we lose and we make $10,000 if we win. Make this kick or I’ll rip you’re [expletive] head off.’ ”
Lowery, who grew up near Washington, D.C., and now lives in Arizona, somehow cultivated a Western Pennsylvanian understanding of the Black & Gold, either through his appreciation of the old Three Rivers crowds or ancient AFC rivalries or from the fact that he was long the next door neighbor of one-time Steelers draft choice Whizzer White. Curiously, White seemed to gain something of a grander status as a sitting justice on the Supreme Court of the United States.
“When you’re looking for heroes,” Lowery said of the late justice, “here’s a guy that led the National Football League in rushing the same year he finished first in his class at Yale Law School.”
But nothing and no one in the Steelers pantheon likely moves Lowery in his public policy role today like the story of Mike Webster, the Hall of Famer who was again so sorely missed on the Steelers’ alumni weekend this month, having been taken from us tragically in 2002 at the age of 50.
Webby and Lowery were teammates for only two years, the seasons Webster spent in Kansas City at the end of his career, 1989 and 1990, but in promoting and accelerating research into Chronic Traumatic Encephalopathy (CTE), Lowery is virtually fueled by his near mythic recollections of Iron Mike.
“Very truthfully, the most powerful, emotional weight in this comes from sitting on the bus with a guy named Mike Webster,” Lowery said. “Mike was talking about how he was looking forward to retirement and he’d purchased some apartment complexes up in Minnesota, looking forward to time with his family. We all know what happened to Mike, but he didn’t know until it was too late.
“Suffering, that word, doesn’t do it any good, doesn’t begin to describe it. It was so much worse than that, not only for him, but for his family. Cognitive impairment, headaches, vertigo, confusion, lack of insight, dementia, bad judgment, sleep issues, anxiety issues, all things my dear teammate had to endure. My motivation is, knowing what [Webster’s wife] Pam’s gone through and the family’s gone through, and the people who knew this was Iron Mike, this was true anchor of that team, the quiet leader I got to play with for two years. He didn’t talk about himself, he just got it done. You’d see him on the sideline and for us, as Chiefs, it was such an important thing to have that human being with us. His loss, what he went through, no one should have to go through.”
This is where Lowery can still get emotional about where the game is heading in terms of head trauma and what can be done about it.
“This is something that we have to do something about, and it’s not because football is a demon — football is the best damn thing; it’s the greatest blessing I’ve ever had,” he said, his voice quaking a bit. “I had to work through getting cut by eight teams 11 times before I made it. All the rich memories I’ve had would not have happened without football and learning about what I was made of. These guys that are dying, they’re some of the greatest guys you could meet in your life.”
As he watched this past week’s sweeping, solemn ceremonies honoring the passing of George H.W. Bush, Lowery almost no doubt felt the swell of pride and inspiration.
“I got to work in the Points of Light Foundation in ’89; I could look out the window and look at George H.W. tossing horseshoes,” Lowery said. “So that’s what my life came to be about and why I went to Harvard, to find out how you become efficient and successful as a leader dealing with very difficult subjects and that’s what I studied – conflict resolution, negotiation, non-profit management, etc.”
On top of the raw emotions he carries from seeing so many contemporaries suffer and die from repetitive brain trauma, Lowery brings an academic’s approach to the problem for which he can now see a potential solution “within a generation.” He can cite case studies and patent numbers and experiments and data and projections in the practiced language of scientists and has become a spokesman for Kannalife Sciences, a Doylestown, Pa., company specializing in the research and development of cannabinoid therapeutics.
Dr. Douglas Brenneman, a Kannalife neuro-pharmacologist, told “Dateline NBC” in May that the cannabis extract CBD might have the capacity, through its pain reducing qualities, to overturn the opioid epidemic. The company hopes CBD’s will one day be used to reverse the toxicity in the brain brought on by repeated concussive trauma and CTE.
“The potential is way up there,” Brenneman said in that segment. “The anecdotal evidence is something that really gets your attention.”
To Lowery and many former players like him, this is the way the NFL’s concussion problem should be attacked, in the best traditions of science and academia.
“What we need to do, just like in every difficult dilemma we’ve ever had in our country, is to learn everything we can about, do the research and work together just to say the game is bigger than us,” he said. “Who are the stewards of this game? The NFL frankly was playing games on this issue until 2010. Since then there have been rule changes. Obviously you see people not liking some of them, but these are the uneven manifestations of trying to get things better. While it’s not where it needs to be, it’s going in the right direction.
“The damn game is bigger than us and we are stewards of the game and our role is to preserve it by doing the right thing.”
Should the NFL one day actually turn the corner on this, I’m guessing it’ll be a lot more significant than Nick the Kick’s overtime dagger in Kansas City that day long ago, or even than who winds up winning the AFC North.
With four weeks remaining in yet another imponderable NFL season, it’s impossible to say whether the Steelers or the Baltimore Ravens will win an AFC North race that is, as the great broadcaster Red Barber liked to say, “tighter than a new pair of shoes on a rainy day.”
Moreover, it’s impossible to know who among the conference’s top contemporary swaggerers — Kansas City, New England, Houston or those Steelers-slaying fresh princes of BelAir, the Los Angeles Chargers — will erect the greatest impediment to Pittsburgh’s perpetual Super Bowl fixation.
But there is, in all of this, one absolute certainty.
Before the playoffs begin, someone will remind the Chiefs, who have the best record in the AFC at 10-2, that they haven’t won a home playoff game in 25 years.
It may as well be Nick Lowery, who long before becoming the first pro athlete to graduate from Harvard’s JFK School of Government with that master’s in public administration, kicked the overtime field goal that beat the Steelers, 27-24, on that bone cold day in Missouri nearly a quarter century ago. It was Jan. 8, 1994.
“I remember thinking, ‘This is the biggest kick of my life,’ and just saying, ‘Trust your training, just trust your training, keep your [darn] head down,’ ” Lowery remembered one day this past week. “And I will never forget, because that was the last kick I ever had in Arrowhead Stadium in my career as a Chief. I’ve got a picture of that in my kitchen, of 80,000 people in red like a huge human wave standing up, and all my teammates running on.”
A three-time Pro Bowler and the leading scorer in Chiefs history, Lowery played for the Patriots and the Jets as well in an 18-year-career that ended in 1996, but he’s still got killer Steelers stories.
“Pro Bowl, 1982, surrealistically beautiful palm trees, beautiful Hawaiian ladies, and there’s Jack Lambert,” this one begins. “And Jack, every night at about 8:30, was going to a country music bar for a couple of beers and sometimes I’d join him, and around the second or third beer they’d challenge him to come up on stage — the band would — and he’d get up and sing pretty well.
“So we had a little bit of a friendship, and we had an amazing team, Don Shula was the coach and Earl Campbell was there and John Hannah, Steve Largent, Dan Fouts. So the game comes and it’s 13-13 late and we’re driving down the field, a game-winning field goal situation, and Lambert comes up to me on the sideline with this toothless smile and says, ‘Rookie (and I wasn’t a rookie), we make $5,000 if we lose and we make $10,000 if we win. Make this kick or I’ll rip you’re [expletive] head off.’ ”
Lowery, who grew up near Washington, D.C., and now lives in Arizona, somehow cultivated a Western Pennsylvanian understanding of the Black & Gold, either through his appreciation of the old Three Rivers crowds or ancient AFC rivalries or from the fact that he was long the next door neighbor of one-time Steelers draft choice Whizzer White. Curiously, White seemed to gain something of a grander status as a sitting justice on the Supreme Court of the United States.
“When you’re looking for heroes,” Lowery said of the late justice, “here’s a guy that led the National Football League in rushing the same year he finished first in his class at Yale Law School.”
But nothing and no one in the Steelers pantheon likely moves Lowery in his public policy role today like the story of Mike Webster, the Hall of Famer who was again so sorely missed on the Steelers’ alumni weekend this month, having been taken from us tragically in 2002 at the age of 50.
Webby and Lowery were teammates for only two years, the seasons Webster spent in Kansas City at the end of his career, 1989 and 1990, but in promoting and accelerating research into Chronic Traumatic Encephalopathy (CTE), Lowery is virtually fueled by his near mythic recollections of Iron Mike.
“Very truthfully, the most powerful, emotional weight in this comes from sitting on the bus with a guy named Mike Webster,” Lowery said. “Mike was talking about how he was looking forward to retirement and he’d purchased some apartment complexes up in Minnesota, looking forward to time with his family. We all know what happened to Mike, but he didn’t know until it was too late.
“Suffering, that word, doesn’t do it any good, doesn’t begin to describe it. It was so much worse than that, not only for him, but for his family. Cognitive impairment, headaches, vertigo, confusion, lack of insight, dementia, bad judgment, sleep issues, anxiety issues, all things my dear teammate had to endure. My motivation is, knowing what [Webster’s wife] Pam’s gone through and the family’s gone through, and the people who knew this was Iron Mike, this was true anchor of that team, the quiet leader I got to play with for two years. He didn’t talk about himself, he just got it done. You’d see him on the sideline and for us, as Chiefs, it was such an important thing to have that human being with us. His loss, what he went through, no one should have to go through.”
This is where Lowery can still get emotional about where the game is heading in terms of head trauma and what can be done about it.
“This is something that we have to do something about, and it’s not because football is a demon — football is the best damn thing; it’s the greatest blessing I’ve ever had,” he said, his voice quaking a bit. “I had to work through getting cut by eight teams 11 times before I made it. All the rich memories I’ve had would not have happened without football and learning about what I was made of. These guys that are dying, they’re some of the greatest guys you could meet in your life.”
As he watched this past week’s sweeping, solemn ceremonies honoring the passing of George H.W. Bush, Lowery almost no doubt felt the swell of pride and inspiration.
“I got to work in the Points of Light Foundation in ’89; I could look out the window and look at George H.W. tossing horseshoes,” Lowery said. “So that’s what my life came to be about and why I went to Harvard, to find out how you become efficient and successful as a leader dealing with very difficult subjects and that’s what I studied – conflict resolution, negotiation, non-profit management, etc.”
On top of the raw emotions he carries from seeing so many contemporaries suffer and die from repetitive brain trauma, Lowery brings an academic’s approach to the problem for which he can now see a potential solution “within a generation.” He can cite case studies and patent numbers and experiments and data and projections in the practiced language of scientists and has become a spokesman for Kannalife Sciences, a Doylestown, Pa., company specializing in the research and development of cannabinoid therapeutics.
Dr. Douglas Brenneman, a Kannalife neuro-pharmacologist, told “Dateline NBC” in May that the cannabis extract CBD might have the capacity, through its pain reducing qualities, to overturn the opioid epidemic. The company hopes CBD’s will one day be used to reverse the toxicity in the brain brought on by repeated concussive trauma and CTE.
“The potential is way up there,” Brenneman said in that segment. “The anecdotal evidence is something that really gets your attention.”
To Lowery and many former players like him, this is the way the NFL’s concussion problem should be attacked, in the best traditions of science and academia.
“What we need to do, just like in every difficult dilemma we’ve ever had in our country, is to learn everything we can about, do the research and work together just to say the game is bigger than us,” he said. “Who are the stewards of this game? The NFL frankly was playing games on this issue until 2010. Since then there have been rule changes. Obviously you see people not liking some of them, but these are the uneven manifestations of trying to get things better. While it’s not where it needs to be, it’s going in the right direction.
“The damn game is bigger than us and we are stewards of the game and our role is to preserve it by doing the right thing.”
Should the NFL one day actually turn the corner on this, I’m guessing it’ll be a lot more significant than Nick the Kick’s overtime dagger in Kansas City that day long ago, or even than who winds up winning the AFC North.
Kannalife Sciences Finalizes Share Exchange Agreement with TYG Solutions Corp.
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange transaction with TYG Solutions Corp. (OTC:TYYG). The closing of this transaction marks an important step in making Kannalife the only publicly traded company in the cannabinoid therapeutics space which holds an exclusive license to a U.S. government patent from the National Institutes of Health (“NIH”).
Eight years ago, as a privately held company, Kannalife embarked on a mission to advance the scientific and potential therapeutic value of cannabinoid therapeutics in treatment of certain diseases. The completion of the share exchange transaction with TYG Solutions Corp. brings the company to another starting point in the company’s history – now as a publicly traded company. This is especially noteworthy as the biotechnology space is in the middle of a very exciting resurgence, coupled with burgeoning investor interest in “anything cannabis.”
“While we certainly don’t consider ourselves an ‘anything cannabis’ company, we haven’t lost sight of the fact that Kannalife was among a select few companies in the pharmaceutical space to approach drug development in cannabinoid therapeutics,” Kannalife Sciences CEO Dean Petkanas said. “We were indeed, not only early movers, but also a pioneer in the pre-clinical research of cannabidiol (CBD) for certain disorders. In that, we have also developed alternative cannabidiol-derived new chemical entities (NCEs) to advance some of the clinical benefits of CBD while improving upon some of the pharmacokinetic limitations of CBD.”
“The transaction with TYYG allows us to look toward the future as a publicly traded company and continue our research into developing disruptive cannabinoid-based therapeutics for neurodegenerative and oxidative stress-related diseases,” Petkanas continued.
Kannalife Sciences currently holds two licenses with NIH. The first, an exclusive license for the commercialization of U.S. Patent #6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”), to research and develop novel cannabinoid-based therapeutics to treat hepatic encephalopathy (HE); and the second, a non-exclusive license under the same ‘507 Patent to treat chronic traumatic encephalopathy (CTE).
Further, Kannalife has developed its own patented molecules led by KLS-13019 and was recently awarded U.S. Patent #9,611,213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy.” According to a February 10, 2016publication in the American Chemical SocietyKLS-13019 was found to be 50-fold more potent as a neuroprotectant and >400-fold safer than CBD.
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy (“HE”) and chronic traumatic encephalopathy (“CTE”). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com.
About TYG Solutions Corp.
TYG Solutions Corp. (OTC:TYYG) is a publicly-traded, SEC reporting company and parent entity of Kannalife Sciences, Inc. For more information, including current SEC filings, visit www.tygsolutionscorp.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Kannalife does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com
NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is pleased to announce the completion of a share exchange transaction with TYG Solutions Corp. (OTC:TYYG). The closing of this transaction marks an important step in making Kannalife the only publicly traded company in the cannabinoid therapeutics space which holds an exclusive license to a U.S. government patent from the National Institutes of Health (“NIH”).
Eight years ago, as a privately held company, Kannalife embarked on a mission to advance the scientific and potential therapeutic value of cannabinoid therapeutics in treatment of certain diseases. The completion of the share exchange transaction with TYG Solutions Corp. brings the company to another starting point in the company’s history – now as a publicly traded company. This is especially noteworthy as the biotechnology space is in the middle of a very exciting resurgence, coupled with burgeoning investor interest in “anything cannabis.”
“While we certainly don’t consider ourselves an ‘anything cannabis’ company, we haven’t lost sight of the fact that Kannalife was among a select few companies in the pharmaceutical space to approach drug development in cannabinoid therapeutics,” Kannalife Sciences CEO Dean Petkanas said. “We were indeed, not only early movers, but also a pioneer in the pre-clinical research of cannabidiol (CBD) for certain disorders. In that, we have also developed alternative cannabidiol-derived new chemical entities (NCEs) to advance some of the clinical benefits of CBD while improving upon some of the pharmacokinetic limitations of CBD.”
“The transaction with TYYG allows us to look toward the future as a publicly traded company and continue our research into developing disruptive cannabinoid-based therapeutics for neurodegenerative and oxidative stress-related diseases,” Petkanas continued.
Kannalife Sciences currently holds two licenses with NIH. The first, an exclusive license for the commercialization of U.S. Patent #6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”), to research and develop novel cannabinoid-based therapeutics to treat hepatic encephalopathy (HE); and the second, a non-exclusive license under the same ‘507 Patent to treat chronic traumatic encephalopathy (CTE).
Further, Kannalife has developed its own patented molecules led by KLS-13019 and was recently awarded U.S. Patent #9,611,213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy.” According to a February 10, 2016publication in the American Chemical SocietyKLS-13019 was found to be 50-fold more potent as a neuroprotectant and >400-fold safer than CBD.
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy (“HE”) and chronic traumatic encephalopathy (“CTE”). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com.
About TYG Solutions Corp.
TYG Solutions Corp. (OTC:TYYG) is a publicly-traded, SEC reporting company and parent entity of Kannalife Sciences, Inc. For more information, including current SEC filings, visit www.tygsolutionscorp.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Kannalife does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com
Nick Lowery on CNBC Revisits Power Hour Talks Kannalife Sciences
Nick Lowery, former Kansas City Chiefs Kicker and Kannalife Spokesperson, visits CNBC’s Power Hour as he holds first place in this years Stock Draft.
Nick Lowery, former Kansas City Chiefs Kicker and Kannalife Spokesperson, visits CNBC’s Power Hour as he holds first place in this years Stock Draft.
CFN Media Interviews Kannalife CEO Dean Petkanas
CFN Media Interviews Dean Petkanas of Kannalife Sciences Inc. at its LA studio.
CFN Media Interviews Dean Petkanas of Kannalife Sciences Inc. at its LA studio.
Kannalife mentioned in BioSpace on the First Cannabis-Based Drug receives FDA Approval
Cannabis-Based Drug Developers Are Hopeful as FDA Approves First Marijuana-based Seizure Treatment – By Alex Keown
In a first of its kind ruling, the U.S. Food and Drug Administration (FDA) approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
The approval of Epidiolex marks two firsts for the U.S. regulatory agency. The GW Pharma drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana. Perhaps more importantly though for patients with Dravet syndrome, the approval is the first FDA treatment for patients with Dravet syndrome.
Cannabidiol (CBD) is a chemical component of the Cannabis sativa plant, more commonly known as marijuana. However, CBD does not cause intoxication. It’s the first in a new category of anti-epileptic drugs (AEDs), GW Pharma said.
“Today’s approval of Epidiolex is a historic milestone, offering patients and their families the first and only FDA-approved CBD medicine to treat two severe, childhood-onset epilepsies,” said Justin Gover, GW’s chief executive officer. “This approval is the culmination of GW’s many years of partnership with patients, their families, and physicians in the epilepsy community to develop a much needed, novel medicine. These patients deserve and will soon have access to a cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and available by prescription under a physician’s care.”
LGS and Dravet syndrome are rare and severe forms of epilepsy that are notoriously treatment-resistant. The diseases typically develop in early childhood. Because of the severity of the type of epilepsy, most patients with LGS and Dravet syndrome require multiple seizure medications and the majority are resistant to currently approved AEDs. The day-to-day impact of these conditions is significant with high rates of early mortality.
Epidiolex will be marketed in the U.S. by Greenwich Biosciences, the U.S. subsidiary of GW Pharmaceuticals plc. But before that can happen, the company must wait for the U.S. Drug Enforcement Administration to reschedule Epidiolex from its current Schedule I status before it can be made available to patients. Rescheduling is expected to occur within 90 days of the FDA approval, the company said. Access is expected to be similar to other branded AEDs and Epidiolex is expected to be available to appropriate patients by the fall of this year. The Europeans Medicine Agency is expected to rule on Epidiolex in the first quarter of 2019.
FDA Commissioner Scott Gottlieb noted that the approval of Epidiolex “serves as a reminder” that understanding and advancing development programs from the active ingredients in marijuana can lead to important medical therapies.
“Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients. Because of the adequate and well-controlled clinical studies that supported this approval, prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes,” Gottlieb said in a statement.
The FDA approved Epidiolex following a Phase III trial that showed the marijuana-based treatment, taken along with other medications, was effective in reducing the frequency of seizures when compared with placebo in 516 patients with either Lennox-Gastaut syndrome or Dravet syndrome. The U.K.-based company will likely be looking for FDA approval of Epidiolex in other indications as well. GW has received Orphan Drug Designation from the FDA for the treatment of tuberous sclerosis complex (TSC) and infantile spasms (IS). GW is currently evaluating additional clinical development programs in other orphan seizure disorders including a Phase III trial in TSC.
GW Pharmaceuticals isn’t the only company working to develop cannabis-based treatments for disease. Other companies developing such treatments include Axim Biotechnologies, which is developing a cannabinoid-based chewing gum delivery method; Kannalife Sciences, which is researching oxidative and neuro-toxic stresses born from a variety of ailments and illnesses including Chronic Pain and Chronic Traumatic Encephalopathy; CURE Pharmaceuticals, which is developing cannabinoids for the treatment of a wide range of sleep disorders; as well as Columbia Care, which struck a licensing agreement with Australia-based nasal respiratory company Rhinomed for the collaborative development of nasally-delivered cannabis-based medicines.
Companies in the cannabis-based treatment space are hoping the FDA approval for Epidiolex will spur additional investors in their own treatments. Dean Petkanas, CEO of Kannalife Sciences, they “anticipate that investment capital may now be more likely to find its way into our end of the space,” due to the GW Pharma drug’s approval.
“We are encouraged by the market approval of Epidiolex as it affirms our judgment and decision to be a pharmaceutical company in what should be a burgeoning industry in the cannabinoid therapeutics market. And to this end, Wall Street may finally drop the old guard mantra that federal regulations prohibit investments in the space,” Petkanas said in a statement.
Cannabis-Based Drug Developers Are Hopeful as FDA Approves First Marijuana-based Seizure Treatment – By Alex Keown
In a first of its kind ruling, the U.S. Food and Drug Administration (FDA) approved GW Pharmaceuticals’ Epidiolex, a cannabis-based treatment for seizures associated with two rare forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
The approval of Epidiolex marks two firsts for the U.S. regulatory agency. The GW Pharma drug is the first FDA-approved drug that contains a purified drug substance derived from marijuana. Perhaps more importantly though for patients with Dravet syndrome, the approval is the first FDA treatment for patients with Dravet syndrome.
Cannabidiol (CBD) is a chemical component of the Cannabis sativa plant, more commonly known as marijuana. However, CBD does not cause intoxication. It’s the first in a new category of anti-epileptic drugs (AEDs), GW Pharma said.
“Today’s approval of Epidiolex is a historic milestone, offering patients and their families the first and only FDA-approved CBD medicine to treat two severe, childhood-onset epilepsies,” said Justin Gover, GW’s chief executive officer. “This approval is the culmination of GW’s many years of partnership with patients, their families, and physicians in the epilepsy community to develop a much needed, novel medicine. These patients deserve and will soon have access to a cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and available by prescription under a physician’s care.”
LGS and Dravet syndrome are rare and severe forms of epilepsy that are notoriously treatment-resistant. The diseases typically develop in early childhood. Because of the severity of the type of epilepsy, most patients with LGS and Dravet syndrome require multiple seizure medications and the majority are resistant to currently approved AEDs. The day-to-day impact of these conditions is significant with high rates of early mortality.
Epidiolex will be marketed in the U.S. by Greenwich Biosciences, the U.S. subsidiary of GW Pharmaceuticals plc. But before that can happen, the company must wait for the U.S. Drug Enforcement Administration to reschedule Epidiolex from its current Schedule I status before it can be made available to patients. Rescheduling is expected to occur within 90 days of the FDA approval, the company said. Access is expected to be similar to other branded AEDs and Epidiolex is expected to be available to appropriate patients by the fall of this year. The Europeans Medicine Agency is expected to rule on Epidiolex in the first quarter of 2019.
FDA Commissioner Scott Gottlieb noted that the approval of Epidiolex “serves as a reminder” that understanding and advancing development programs from the active ingredients in marijuana can lead to important medical therapies.
“Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients. Because of the adequate and well-controlled clinical studies that supported this approval, prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes,” Gottlieb said in a statement.
The FDA approved Epidiolex following a Phase III trial that showed the marijuana-based treatment, taken along with other medications, was effective in reducing the frequency of seizures when compared with placebo in 516 patients with either Lennox-Gastaut syndrome or Dravet syndrome. The U.K.-based company will likely be looking for FDA approval of Epidiolex in other indications as well. GW has received Orphan Drug Designation from the FDA for the treatment of tuberous sclerosis complex (TSC) and infantile spasms (IS). GW is currently evaluating additional clinical development programs in other orphan seizure disorders including a Phase III trial in TSC.
GW Pharmaceuticals isn’t the only company working to develop cannabis-based treatments for disease. Other companies developing such treatments include Axim Biotechnologies, which is developing a cannabinoid-based chewing gum delivery method; Kannalife Sciences, which is researching oxidative and neuro-toxic stresses born from a variety of ailments and illnesses including Chronic Pain and Chronic Traumatic Encephalopathy; CURE Pharmaceuticals, which is developing cannabinoids for the treatment of a wide range of sleep disorders; as well as Columbia Care, which struck a licensing agreement with Australia-based nasal respiratory company Rhinomed for the collaborative development of nasally-delivered cannabis-based medicines.
Companies in the cannabis-based treatment space are hoping the FDA approval for Epidiolex will spur additional investors in their own treatments. Dean Petkanas, CEO of Kannalife Sciences, they “anticipate that investment capital may now be more likely to find its way into our end of the space,” due to the GW Pharma drug’s approval.
“We are encouraged by the market approval of Epidiolex as it affirms our judgment and decision to be a pharmaceutical company in what should be a burgeoning industry in the cannabinoid therapeutics market. And to this end, Wall Street may finally drop the old guard mantra that federal regulations prohibit investments in the space,” Petkanas said in a statement.
Kannalife Spokesperson and former NFL kicker Nick Lowery Talks CTE and CBD on Good Morning San Diego
Dateline NBC with Lester Holt profiles Kannalife on show “Growing Promise”
Kannalife scientist Dr. Doug Brenneman and CEO Dean Petkanas were interviewed by journalist Harry Smith on Dateline NBC Special “Growing Promise” which aired on Sunday May 20, 2018. The topics discussed were cannabidiol (cbd), the 507 Patent (#6630507) “Cannabinoids as Antioxidants and Neuroprotectants” and how CBD can “protect” the brain from neurotoxins, neurodegeneration and potentially treat diseases such as Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE).
Kannalife scientist Dr. Doug Brenneman and CEO Dean Petkanas were interviewed by journalist Harry Smith on Dateline NBC Special “Growing Promise” which aired on Sunday May 20, 2018. The topics discussed were cannabidiol (cbd), the 507 Patent (#6630507) “Cannabinoids as Antioxidants and Neuroprotectants” and how CBD can “protect” the brain from neurotoxins, neurodegeneration and potentially treat diseases such as Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE).
Kannalife Sciences to be Featured in Dateline NBC Segment Covering Company’s Research on CBD-Like Molecules as Treatments for HE, CTE
NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is excited to announce that the Company will be featured in a Dateline NBC segment discussing how their research on cannabidiol (CBD)-like molecules could potentially change the landscape for various ailments including chronic traumatic encephalopathy (CTE) and the opioid epidemic.
The Kannalife-centric segment will air at 7:00pm EDT, during the Sunday, May 20th, episode of Dateline NBC. The segment will take an in-depth look into Kannalife Sciences and their groundbreaking research investigating whether the Company’s proprietary CBD-like molecules can help change the medical landscape and offer several new treatments for specific ailments.
“We are excited to be a part of this Dateline NBC special, dedicated to the therapeutic benefits of cannabinoids derived from the cannabis plant, cannabinoid-like molecules and how companies like Kannalife are working to conduct the necessary research to bring new drugs to market,” said Kannalife Sciences CEO Dean Petkanas. “This kind of exposure helps us communicate the health and wellness benefits of CBD and CBD-like molecules, as well as new potential treatments for CTE.”
A good portion of this news piece will focus on the problem of CTE, a degenerative neurological disease caused by repeated head trauma that can lead to symptoms like violent mood swings, depression and other cognitive difficulties. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
Kannalife Sciences currently holds two licenses, one of them exclusive, with the National Institutes of Health (NIH) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants”, to research Hepatic Encephalopathy (HE) and CTE.
Additionally, with over 20,000 deaths a year related to prescription opioids, Kannalife discusses the potential benefits of using cannabis as a replacement for opioids to not only help those suffering from addiction but as an alternative to opioids to treat chronic pain.
About Kannalife Sciences
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants”. Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat HE and CTE. HE and CTE are oxidative stress related diseases that affect the cognitive and behavioral functions, and the wellness of the brain.
NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is excited to announce that the Company will be featured in a Dateline NBC segment discussing how their research on cannabidiol (CBD)-like molecules could potentially change the landscape for various ailments including chronic traumatic encephalopathy (CTE) and the opioid epidemic.
The Kannalife-centric segment will air at 7:00pm EDT, during the Sunday, May 20th, episode of Dateline NBC. The segment will take an in-depth look into Kannalife Sciences and their groundbreaking research investigating whether the Company’s proprietary CBD-like molecules can help change the medical landscape and offer several new treatments for specific ailments.
“We are excited to be a part of this Dateline NBC special, dedicated to the therapeutic benefits of cannabinoids derived from the cannabis plant, cannabinoid-like molecules and how companies like Kannalife are working to conduct the necessary research to bring new drugs to market,” said Kannalife Sciences CEO Dean Petkanas. “This kind of exposure helps us communicate the health and wellness benefits of CBD and CBD-like molecules, as well as new potential treatments for CTE.”
A good portion of this news piece will focus on the problem of CTE, a degenerative neurological disease caused by repeated head trauma that can lead to symptoms like violent mood swings, depression and other cognitive difficulties. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
Kannalife Sciences currently holds two licenses, one of them exclusive, with the National Institutes of Health (NIH) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants”, to research Hepatic Encephalopathy (HE) and CTE.
Additionally, with over 20,000 deaths a year related to prescription opioids, Kannalife discusses the potential benefits of using cannabis as a replacement for opioids to not only help those suffering from addiction but as an alternative to opioids to treat chronic pain.
About Kannalife Sciences
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants”. Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat HE and CTE. HE and CTE are oxidative stress related diseases that affect the cognitive and behavioral functions, and the wellness of the brain.
Former NFL great Nick Lowery talks Kannalife on CNBC
Former NFL players Nick Lowery and Eric Dickerson on CNBC.
KannaLife Sciences Announces Nick Lowery as New Spokesperson
Doylestown, PA – Sept. 22, 2017 / Kannalife Sciences, Inc., a pharmaceutical and phyto-medical company, announced today that former three time NFL Pro-Bowl and Kansas City Chiefs placekicker, Nick Lowery, has joined Kannalife corporate advisory board to lead the Company’s initiative on speaking about chronic traumatic encephalopathy (CTE) and Kannalife’s efforts to bring forth a clinically approved treatment for CTE. Kannalife Sciences holds the exclusive license from the federal government to commercialize a cannabinoid patent currently held by the U.S. Government and National Institutes of Health (NIH).
CTE is a degenerative neurological disease caused by repeated head trauma and is only diagnosed with certainty in post-mortem examinations. CTE can lead to symptoms like violent mood swings, depression and other cognitive difficulties. The evidence of severe CTE was seen this week in the latest brain autopsy of NFL player and New England Patriots Tight-End Aaron Hernandez. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
“When Nick and I first met, we drilled down on the great need to bridge the divide being caused by the split narratives regarding CTE – none of which addressed the need for funding clinical research for a treatment. We both believe that through the use of our current license with NIH which centers on the use of cannabidiol as a neuroprotectant, Kannalife can take the lead in working with the NFL to reach the desired goal of helping the many suffering with this terrible disease. Having Nick, a highly respected alumnist of the NFL can not only assist in our objective on the therapeutic side of the equation but also be the face that brings the severity of CTE and concussive injury to the public’s attention with the emphasis placed on solutions rather than irresponsible rhetoric,” said Dean Petkanas, CEO of Kannalife Sciences, Inc.
Nick Lowery will be appearing on Good Morning Arizona talk show at 6:45 a.m. on Saturday September 23, 2017. During these speaking engagements he will be discussing CTE and how devastating it can be on those suffering from this almost invisible disease as well as how KannaLife is looking to work with the NFL to help create a potential safer option for players.
About KannaLife Sciences Kannalife Sciences, Inc. is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”)for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants“ (the “‘507 Patent”). Further, Kannalife has developed its own patented molecules lead by KLS-13019 and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy”. Kannalife is currently conducting research and development at the Bucks CountyPennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
About Medical Marijuana, Inc. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
Doylestown, PA – Sept. 22, 2017 / Kannalife Sciences, Inc., a pharmaceutical and phyto-medical company, announced today that former three time NFL Pro-Bowl and Kansas City Chiefs placekicker, Nick Lowery, has joined Kannalife corporate advisory board to lead the Company’s initiative on speaking about chronic traumatic encephalopathy (CTE) and Kannalife’s efforts to bring forth a clinically approved treatment for CTE. Kannalife Sciences holds the exclusive license from the federal government to commercialize a cannabinoid patent currently held by the U.S. Government and National Institutes of Health (NIH).
CTE is a degenerative neurological disease caused by repeated head trauma and is only diagnosed with certainty in post-mortem examinations. CTE can lead to symptoms like violent mood swings, depression and other cognitive difficulties. The evidence of severe CTE was seen this week in the latest brain autopsy of NFL player and New England Patriots Tight-End Aaron Hernandez. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
“When Nick and I first met, we drilled down on the great need to bridge the divide being caused by the split narratives regarding CTE – none of which addressed the need for funding clinical research for a treatment. We both believe that through the use of our current license with NIH which centers on the use of cannabidiol as a neuroprotectant, Kannalife can take the lead in working with the NFL to reach the desired goal of helping the many suffering with this terrible disease. Having Nick, a highly respected alumnist of the NFL can not only assist in our objective on the therapeutic side of the equation but also be the face that brings the severity of CTE and concussive injury to the public’s attention with the emphasis placed on solutions rather than irresponsible rhetoric,” said Dean Petkanas, CEO of Kannalife Sciences, Inc.
Nick Lowery will be appearing on Good Morning Arizona talk show at 6:45 a.m. on Saturday September 23, 2017. During these speaking engagements he will be discussing CTE and how devastating it can be on those suffering from this almost invisible disease as well as how KannaLife is looking to work with the NFL to help create a potential safer option for players.
About KannaLife Sciences Kannalife Sciences, Inc. is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”)for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants“ (the “‘507 Patent”). Further, Kannalife has developed its own patented molecules lead by KLS-13019 and was recently awarded U.S. Patent #9611213, “Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy”. Kannalife is currently conducting research and development at the Bucks CountyPennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). HE and CTE are both oxidative stress related diseases that affects the cognitive and behavioral functions, and the wellness of the brain.
About Medical Marijuana, Inc. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
Kannalife Sciences Participates in 27th Annual International Cannabinoid Research Society (ICRS) Symposium Company Presents Science Behind Mechanism of Action of CBD and its Own Patented CBD-derived Molecule KLS-13019
Kannalife Sciences Participates in 27th Annual International Cannabinoid Research Society (ICRS) Symposium
Company Presents Science Behind Mechanism of Action of CBD and its Own Patented CBD-derived Molecule KLS-13019
NEW YORK, July 5, 2017 — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, announced today that it presented its findings at the 27th Annual ICRS Symposium on the Cannabinoids held in Montreal, Canada from June 22-27, 2017. The Company presented one of its published bodies of science titled the “Effect of KLS-13019 and Cannabidiol On Neuroprotection from Oxidative Stress in Hippocampal Cultures: Mechanism of Action” and two posters at the Symposium.
The publication and two posters Kannalife presented at the Symposium, titled “Neuroprotective and Anti-Inflammatory Effects of KLS-13109 and Cannabidiol in IN VITRO and IN VIVO Models of Chemotherapy-Induced Neuropathic Pain” and “Discovery of Side-Chain Modified Cannabidiol-Derived Neuroprotective Agents with Improved “Drug Likeness,” highlighted the Company’s recent research of CBD and CBD-derived molecule target drug candidates to treat neurodegenerative diseases.
“When we set out to design a better molecule and keep much of the pharmacological properties of CBD such as neuroprotection and reducing oxidative stress, we hoped to come up with an answer to the limitations of CBD,” said CEO of Kannalife, Dean Petkanas. “We believe we’ve answered that problem with KLS-13019. Accordingly, we were honored and grateful to be given the opportunity by the ICRS to present our Company’s most recent research and progress in the field of cannabinoid-based therapeutics. The ICRS is dedicated to promoting the exchange of scientific information and perspectives about the use of cannabis, cannabinoid therapeutics, in the regulation of receptors, neurotransmitters and homeostasis of the endocannabinoid system. Their involvement in sponsoring an annual event that pushes forth the field of scientific discovery in cannabinoid therapeutics is unparalleled.”
Kannalife currently holds a patent on KLS-13019 and other new chemical entities (NCEs) in this class of cannabidiol-derived molecules. The Company also holds two license agreements with the National Institutes of Health (NIH) to utilize the US Government Patent (#6,630,507) on the therapeutic usage of cannabinoids, which derive from the cannabis plant family (industrial hemp or marijuana). The Company is presently conducting research at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (HE), Chemotherapy Induced Neuropathic Pain (CINP) and Chronic Traumatic Encephalopathy (CTE). Both HE and CTE are oxidative stress diseases that affect cognitive and behavioral function.
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com.
Kannalife Sciences Participates in 27th Annual International Cannabinoid Research Society (ICRS) Symposium
Company Presents Science Behind Mechanism of Action of CBD and its Own Patented CBD-derived Molecule KLS-13019
NEW YORK, July 5, 2017 — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, announced today that it presented its findings at the 27th Annual ICRS Symposium on the Cannabinoids held in Montreal, Canada from June 22-27, 2017. The Company presented one of its published bodies of science titled the “Effect of KLS-13019 and Cannabidiol On Neuroprotection from Oxidative Stress in Hippocampal Cultures: Mechanism of Action” and two posters at the Symposium.
The publication and two posters Kannalife presented at the Symposium, titled “Neuroprotective and Anti-Inflammatory Effects of KLS-13109 and Cannabidiol in IN VITRO and IN VIVO Models of Chemotherapy-Induced Neuropathic Pain” and “Discovery of Side-Chain Modified Cannabidiol-Derived Neuroprotective Agents with Improved “Drug Likeness,” highlighted the Company’s recent research of CBD and CBD-derived molecule target drug candidates to treat neurodegenerative diseases.
“When we set out to design a better molecule and keep much of the pharmacological properties of CBD such as neuroprotection and reducing oxidative stress, we hoped to come up with an answer to the limitations of CBD,” said CEO of Kannalife, Dean Petkanas. “We believe we’ve answered that problem with KLS-13019. Accordingly, we were honored and grateful to be given the opportunity by the ICRS to present our Company’s most recent research and progress in the field of cannabinoid-based therapeutics. The ICRS is dedicated to promoting the exchange of scientific information and perspectives about the use of cannabis, cannabinoid therapeutics, in the regulation of receptors, neurotransmitters and homeostasis of the endocannabinoid system. Their involvement in sponsoring an annual event that pushes forth the field of scientific discovery in cannabinoid therapeutics is unparalleled.”
Kannalife currently holds a patent on KLS-13019 and other new chemical entities (NCEs) in this class of cannabidiol-derived molecules. The Company also holds two license agreements with the National Institutes of Health (NIH) to utilize the US Government Patent (#6,630,507) on the therapeutic usage of cannabinoids, which derive from the cannabis plant family (industrial hemp or marijuana). The Company is presently conducting research at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (HE), Chemotherapy Induced Neuropathic Pain (CINP) and Chronic Traumatic Encephalopathy (CTE). Both HE and CTE are oxidative stress diseases that affect cognitive and behavioral function.
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com.
Letter from our CEO
Last week the U.S. Drug Enforcement Administration (“DEA”) made an unexpected ruling regarding the ongoing scheduling of cannabis (aka: marijuana). After much deliberation, almost a full year in the waiting, the DEA announced that there will be no change to the current scheduling of marijuana and it remain listed as a schedule 1 controlled substance. The DEA did give guidance that they support continued scientific research on cannabis and its constituents and that any findings that lead towards medicinal value should further be taken through the U.S. Food and Drug Administration (“FDA”) for clinical trials and subsequent approval (see: http://apps.npr.org/documents/document.html?id=3010607-AA-Rosenberg-Marijuana-Petition-Ltr-08-11-2016)
This news from the DEA validates our business model and our efforts from our inception. Since 2010, Kannalife Sciences, Inc. (“Kannalife”) has taken a scientific, “by the book” approach, meeting the strict DEA and FDA criteria to researching and developing our target drug candidates, namely cannabidiol (CBD) and cannabidiol-derived molecules.
We commend the DEA and respect their position as the FDA drug approval process is the most appropriate way to assess whether a product derived from marijuana or its constituents is safe and effective and has an accepted medical use.
Prior to the news from the DEA, Kannalife was featured in July in Sports Illustrated (see: http://www.si.com/nfl/2016/07/12/cannabis-cte-treatment-kannalife). This feature story in Sports Illustrated draws attention to the serious nature of concussive injury and the work Kannalife is doing to find a treatment for the concussion related disease known as Chronic Traumatic Encephalopathy (CTE) which has and continues to plague contact sports athletes, primarily football players.
In addition to the work we are currently doing on CTE, to date, we have completed 90% of our pre-clinical research for an orphan disease known as Hepatic Encephalopathy (HE). In our pharmacokinetic and pharmacodynamic studies we’ve looked to CBD as a positive control and compared it to KLS-13019, our proprietary novel cannabidiol-derived molecule. The results on KLS-13019 have shown that, while CBD has great potential, KLS-13019 has even greater potential to treat late stage neurodegenerative diseases (see: ACS Med. Chem. Lett. 2016, 7 (4) pp 424-428 – http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00009)
By way of background, Kannalife, founded in 2010, focuses primarily on the research, development and commercial use of cannabinoid therapeutics to treat neurodegenerative diseases. Kannalife is the only company in the world that has licensed the use of U.S. Patent 6630507 “Cannabinoids as Antioxidants and Neuroprotectants”, from National Institutes of Health (“NIH”), also patented in the UK; European Union; Ireland; and Australia.
In addition to the IP licenses with NIH, we have filed our own global patent cooperation treaty (PCT) application and have received favorable review prior to publication in 2015. In addition to the U.S. fling, our non-provisional PCT application has also been filed in the European Union, Japan, China, Russia, Canada, Brazil, India, and Australia. Our PCT patent includes several other molecules in addition to KLS-13019 and has been filed for the potential to treat other diseases such as epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, Parkinson’s disease, Alzheimer’s, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).
As we look at the level of investor interest in the “marijuana space”, and considering that many private equity groups; family offices; venture capital groups and high net worth investors have spent a full year getting their powder dry for the eventuality that the DEA would reschedule cannabis (aka: marijuana), we now believe that attention should be put squarely on Kannalife.
We believe that Kannalife merits a high degree of interest as a company that is prepared to drive investor returns in a remarkably similar fashion to the likes of other pharmaceutical companies in the cannabinoid therapeutics space (namely, GW Pharmaceuticals – GWPH:Nasdaq / Zynerba Pharmaceuticals – ZYNE:Nasdaq / Insys Therapeutics – INSY:Nasdaq)
If you would like to learn more about our current offering opportunity and how to make a strategic investment in Kannalife, please contact our Chief Financial Officer, Mark Corrao at: mark@kannalife.com. After you have had an opportunity to touch base with Mark and review our collateral materials, I would be happy to join you on a conference call to discuss the investment opportunity in Kannalife as well as our immediate and long term goals.
We look forward to hearing from you
Best Regards,
Dean Petkanas
CEO
Kannalife Sciences Inc.
Last week the U.S. Drug Enforcement Administration (“DEA”) made an unexpected ruling regarding the ongoing scheduling of cannabis (aka: marijuana). After much deliberation, almost a full year in the waiting, the DEA announced that there will be no change to the current scheduling of marijuana and it remain listed as a schedule 1 controlled substance. The DEA did give guidance that they support continued scientific research on cannabis and its constituents and that any findings that lead towards medicinal value should further be taken through the U.S. Food and Drug Administration (“FDA”) for clinical trials and subsequent approval (see: http://apps.npr.org/documents/document.html?id=3010607-AA-Rosenberg-Marijuana-Petition-Ltr-08-11-2016)
This news from the DEA validates our business model and our efforts from our inception. Since 2010, Kannalife Sciences, Inc. (“Kannalife”) has taken a scientific, “by the book” approach, meeting the strict DEA and FDA criteria to researching and developing our target drug candidates, namely cannabidiol (CBD) and cannabidiol-derived molecules.
We commend the DEA and respect their position as the FDA drug approval process is the most appropriate way to assess whether a product derived from marijuana or its constituents is safe and effective and has an accepted medical use.
Prior to the news from the DEA, Kannalife was featured in July in Sports Illustrated (see: http://www.si.com/nfl/2016/07/12/cannabis-cte-treatment-kannalife). This feature story in Sports Illustrated draws attention to the serious nature of concussive injury and the work Kannalife is doing to find a treatment for the concussion related disease known as Chronic Traumatic Encephalopathy (CTE) which has and continues to plague contact sports athletes, primarily football players.
In addition to the work we are currently doing on CTE, to date, we have completed 90% of our pre-clinical research for an orphan disease known as Hepatic Encephalopathy (HE). In our pharmacokinetic and pharmacodynamic studies we’ve looked to CBD as a positive control and compared it to KLS-13019, our proprietary novel cannabidiol-derived molecule. The results on KLS-13019 have shown that, while CBD has great potential, KLS-13019 has even greater potential to treat late stage neurodegenerative diseases (see: ACS Med. Chem. Lett. 2016, 7 (4) pp 424-428 – http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00009)
By way of background, Kannalife, founded in 2010, focuses primarily on the research, development and commercial use of cannabinoid therapeutics to treat neurodegenerative diseases. Kannalife is the only company in the world that has licensed the use of U.S. Patent 6630507 “Cannabinoids as Antioxidants and Neuroprotectants”, from National Institutes of Health (“NIH”), also patented in the UK; European Union; Ireland; and Australia.
In addition to the IP licenses with NIH, we have filed our own global patent cooperation treaty (PCT) application and have received favorable review prior to publication in 2015. In addition to the U.S. fling, our non-provisional PCT application has also been filed in the European Union, Japan, China, Russia, Canada, Brazil, India, and Australia. Our PCT patent includes several other molecules in addition to KLS-13019 and has been filed for the potential to treat other diseases such as epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, Parkinson’s disease, Alzheimer’s, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).
As we look at the level of investor interest in the “marijuana space”, and considering that many private equity groups; family offices; venture capital groups and high net worth investors have spent a full year getting their powder dry for the eventuality that the DEA would reschedule cannabis (aka: marijuana), we now believe that attention should be put squarely on Kannalife.
We believe that Kannalife merits a high degree of interest as a company that is prepared to drive investor returns in a remarkably similar fashion to the likes of other pharmaceutical companies in the cannabinoid therapeutics space (namely, GW Pharmaceuticals – GWPH:Nasdaq / Zynerba Pharmaceuticals – ZYNE:Nasdaq / Insys Therapeutics – INSY:Nasdaq)
If you would like to learn more about our current offering opportunity and how to make a strategic investment in Kannalife, please contact our Chief Financial Officer, Mark Corrao at: mark@kannalife.com. After you have had an opportunity to touch base with Mark and review our collateral materials, I would be happy to join you on a conference call to discuss the investment opportunity in Kannalife as well as our immediate and long term goals.
We look forward to hearing from you
Best Regards,
Dean Petkanas
CEO
Kannalife Sciences Inc.
DEA decision on Cannabis aligns with Kannalife’s focus
For over 6 years now, Kannalife Sciences has taken a scientific “by the book” approach meeting the strict DEA and FDA criteria to researching and developing cannabinoids. We have spent time understanding the cannabinoids safety & efficacy profiles to deliver the best available pharmaceutical medicine.
We commend the DEA and respect their position as the “FDA drug approval process is the most appropriate way to assess whether a product derived from marijuana or its constituents is safe and effective and has an accepted medical use.”
See below the letter from the DEA in response to the petition (courtesy of NPR):
For over 6 years now, Kannalife Sciences has taken a scientific “by the book” approach meeting the strict DEA and FDA criteria to researching and developing cannabinoids. We have spent time understanding the cannabinoids safety & efficacy profiles to deliver the best available pharmaceutical medicine.
We commend the DEA and respect their position as the “FDA drug approval process is the most appropriate way to assess whether a product derived from marijuana or its constituents is safe and effective and has an accepted medical use.”
See below the letter from the DEA in response to the petition (courtesy of NPR):
Kannalife featured in Sports Illustrated
How cannabis is helping one company research treatment of CTE
by Ben Baskin –
Imagine if you said to Paul Tagliabue, back in 2003, that Ricky Williams might one day be able to save Junior Seau’s life…”— Thoma Kikis, co-founder of Kannalife Sciences
Imagine that it’s the year 2025. In locker rooms across the NFL, as ankles are taped and braces strapped on, trainers hand out gel capsules for players to ingest minutes before they take the field. The capsules are scientifically designed to protect against the deleterious effect of concussive blows to the head and traumatic brain injury—and, as a result, they have helped to sustain the viability of the sport of football. Oh, and yeah, they are derived from marijuana.
That’s the bet those at Kannalife Sciences are making about our future reality. Kannalife is an independent pharmaceutical company that has entered into a burgeoning, and lucrative, new industry: the study of the cannabis plant and its chemical constituents for therapeutic value. They believe they have found something, something still relatively unknown and very much in its nascent stages, yet something they say has shown great promise as a neuroprotectant. Something that could change the landscape of how brain injuries of all varieties—from chronic traumatic encephalopathy (CTE) to Alzheimer’s and Parkinson’s—will eventually be treated.
Imagine if you said to Paul Tagliabue, back in 2003, that Ricky Williams might one day be able to save Junior Seau’s life…”— Thoma Kikis, co-founder of Kannalife Sciences
Imagine that it’s the year 2025. In locker rooms across the NFL, as ankles are taped and braces strapped on, trainers hand out gel capsules for players to ingest minutes before they take the field. The capsules are scientifically designed to protect against the deleterious effect of concussive blows to the head and traumatic brain injury—and, as a result, they have helped to sustain the viability of the sport of football. Oh, and yeah, they are derived from marijuana.
That’s the bet those at Kannalife Sciences are making about our future reality. Kannalife is an independent pharmaceutical company that has entered into a burgeoning, and lucrative, new industry: the study of the cannabis plant and its chemical constituents for therapeutic value. They believe they have found something, something still relatively unknown and very much in its nascent stages, yet something they say has shown great promise as a neuroprotectant. Something that could change the landscape of how brain injuries of all varieties—from chronic traumatic encephalopathy (CTE) to Alzheimer’s and Parkinson’s—will eventually be treated.
The US Drug Enforcement Agency (DEA) has granted permission for the import of pharmaceutical-grade cannabidiol to Catalent Pharma Solutions for a feasibility study in conjunction with Kannalife Sciences, according to a company press release. Upon completion of the feasibility study, Kannalife will investigate the product’s ability to treat hepatic encephalopathy and chronic traumatic encephalopathy, which are neurodegenerative conditions. Additional research and development for the drug candidates will occur at The Pennsylvania Biotechnology Center in Doylestown, PA, and in other contract manufacturing facilities designated by Kannalife’s scientific team.
Kannalife’s research is bolstered by two licenses from the National Institutes for Health for a patent “Cannabinoids as Antioxidants and Neuroprotectants.” Specifically, the patent, licensed by Kannalife, claims cannabidiol could be used to prevent “glutamate-induced damage in the central nervous system,” among other things. The company’s specific product of interest, KLS-13019, is a novel cannabidiol-like therapeutic compound that is being investigated as a possible treatment for oxidative stress-related diseases.
Kannalife teamed up with Catalent to conduct feasibility studies to investigate shelf stability and dose-dependent administration of the cannabidiol drug target being formulated for the company’s cannabinoid-derived therapeutic agent. The information gleaned from the feasibility studies will help Kannalife further its preclinical development of the target drug candidate and the company’s filing of an investigational new drug (IND) application for clinical studies in humans.
The cannabidiol procured by Kannalife, which itself has no psychoactive effect, is a synthetic white solid that is not naturally derived, Kannalife CEO, Dean Petkanas, told BioPharm International. The sources for this synthetic product within the United States were limited, he noted, and the company needed a large quantity of this raw API to conduct feasibility studies. Although Petkanas said there were a few potential suppliers in the US, “capacity was constrained,” and therefore, the synthetic product had to be imported from a supplier outside of the country.
Similar cannabis-based formulations and structural analogs of cannabidiol by other drug companies are currently in development for the treatment of other chronic conditions. One such company recently in the news is GW Pharmaceuticals. The combination of research on cannabidiol oil by GW and the company’s IND applications, coupled with the medical claims of online companies marketing and selling CBD oil, prompted FDA to send warning letters to these online merchants in early February 2016. Because CBD oil is being examined for its medicinal properties in an IND, it cannot be considered a dietary supplement—and thus, cannot be sold online under these pretenses, the FDA said in the warning letters.
The US Drug Enforcement Agency (DEA) has granted permission for the import of pharmaceutical-grade cannabidiol to Catalent Pharma Solutions for a feasibility study in conjunction with Kannalife Sciences, according to a company press release. Upon completion of the feasibility study, Kannalife will investigate the product’s ability to treat hepatic encephalopathy and chronic traumatic encephalopathy, which are neurodegenerative conditions. Additional research and development for the drug candidates will occur at The Pennsylvania Biotechnology Center in Doylestown, PA, and in other contract manufacturing facilities designated by Kannalife’s scientific team.
Kannalife’s research is bolstered by two licenses from the National Institutes for Health for a patent “Cannabinoids as Antioxidants and Neuroprotectants.” Specifically, the patent, licensed by Kannalife, claims cannabidiol could be used to prevent “glutamate-induced damage in the central nervous system,” among other things. The company’s specific product of interest, KLS-13019, is a novel cannabidiol-like therapeutic compound that is being investigated as a possible treatment for oxidative stress-related diseases.
Kannalife teamed up with Catalent to conduct feasibility studies to investigate shelf stability and dose-dependent administration of the cannabidiol drug target being formulated for the company’s cannabinoid-derived therapeutic agent. The information gleaned from the feasibility studies will help Kannalife further its preclinical development of the target drug candidate and the company’s filing of an investigational new drug (IND) application for clinical studies in humans.
The cannabidiol procured by Kannalife, which itself has no psychoactive effect, is a synthetic white solid that is not naturally derived, Kannalife CEO, Dean Petkanas, told BioPharm International. The sources for this synthetic product within the United States were limited, he noted, and the company needed a large quantity of this raw API to conduct feasibility studies. Although Petkanas said there were a few potential suppliers in the US, “capacity was constrained,” and therefore, the synthetic product had to be imported from a supplier outside of the country.
Similar cannabis-based formulations and structural analogs of cannabidiol by other drug companies are currently in development for the treatment of other chronic conditions. One such company recently in the news is GW Pharmaceuticals. The combination of research on cannabidiol oil by GW and the company’s IND applications, coupled with the medical claims of online companies marketing and selling CBD oil, prompted FDA to send warning letters to these online merchants in early February 2016. Because CBD oil is being examined for its medicinal properties in an IND, it cannot be considered a dietary supplement—and thus, cannot be sold online under these pretenses, the FDA said in the warning letters.
Kannalife eyes share float to fund cannabis-based medicine
Feb 25 Kannalife Sciences Inc is considering an initial public offering this year to fund development of a cannabis-based treatment for a brain disorder that affects 200,000 Americans, its chief executive said.
A successful listing in an unforgiving IPO market would be a springboard for the Huntington, New York-based company to develop an experimental drug that has shown promise in treating a condition known as hepatic encephalopathy (HE).
“We have a good shot on goal with HE,” said Dean Petkanas, Kannalife’s CEO and co-founder. “We want to shoot the puck. If we do that and we score, then our other desires in the field of cannabinoid therapeutics can become self-evident.”
About 1.5 million Americans suffer from HE, a decline in brain function that results from severe liver disease, whereby toxins build up in the bloodstream. About 200,000 people have late stage, or Grade 3, HE, according to Kannalife.
Kannalife’s HE drug, KLS-13019, is derived from synthetic cannabis. Preclinical data published this month showed it to be safer and significantly more potent than pure cannabidiol in protecting brain cells.
“We believe we can push KLS-13019 into clinical trials, but first we need to raise capital,” Petkanas, who has more than 25 years’ experience in investment banking and capital markets, said in an interview.
Kannalife, founded in 2010, raised $1.5 million in a first round of funding three years ago. It aims to raise $5 million to $10 million in a second round within the next 90 days.
That would be sufficient to see the company proceed to clinical trials by the first quarter of 2017, Petkanas said.
Kannalife would then consider an IPO, a bold move at a time when biotechnology stocks are reeling from political criticism of drug prices. The Nasdaq Biotechnology index had fallen nearly 24 percent this year through Wednesday’s close.
More generally, a tepid U.S. market for IPOs has raised just $253 million so far this year, compared with $4 billion in the corresponding year-earlier period.
“We’re throwing the ball in the air right now, because the dynamics of the market have changed considerably in the last six months,” said Petkanas.
As well as its HE drug, Kannalife is conducting a feasibility study into the development of a preventative treatment, also derived from synthetic cannabis, for chronic traumatic encephalopathy (CTE).
CTE is a brain condition resulting from repeated blows to the head, which is poorly understood and has no existing treatment. A sure-shot diagnosis can only be made after death.
For this study, Kannalife has procured a permit from the U.S. Drug Enforcement Administration to import a limited amount of pure cannabidiol, a non-psychoactive component of the Cannabis sativa plant.
John Kagia, director of industry analytics at cannabis-focused data firm New Frontier, said the drug had significant potential due to the extent to which CTE has become an issue for football players and the military.
“The successful deployment of cannabis within these two communities could be a watershed moment in the way the general population thinks about the therapeutic applications of marijuana,” he said. (Reporting by Natalie Grover in Bengaluru; Editing by Robin Paxton)
Feb 25 Kannalife Sciences Inc is considering an initial public offering this year to fund development of a cannabis-based treatment for a brain disorder that affects 200,000 Americans, its chief executive said.
A successful listing in an unforgiving IPO market would be a springboard for the Huntington, New York-based company to develop an experimental drug that has shown promise in treating a condition known as hepatic encephalopathy (HE).
“We have a good shot on goal with HE,” said Dean Petkanas, Kannalife’s CEO and co-founder. “We want to shoot the puck. If we do that and we score, then our other desires in the field of cannabinoid therapeutics can become self-evident.”
About 1.5 million Americans suffer from HE, a decline in brain function that results from severe liver disease, whereby toxins build up in the bloodstream. About 200,000 people have late stage, or Grade 3, HE, according to Kannalife.
Kannalife’s HE drug, KLS-13019, is derived from synthetic cannabis. Preclinical data published this month showed it to be safer and significantly more potent than pure cannabidiol in protecting brain cells.
“We believe we can push KLS-13019 into clinical trials, but first we need to raise capital,” Petkanas, who has more than 25 years’ experience in investment banking and capital markets, said in an interview.
Kannalife, founded in 2010, raised $1.5 million in a first round of funding three years ago. It aims to raise $5 million to $10 million in a second round within the next 90 days.
That would be sufficient to see the company proceed to clinical trials by the first quarter of 2017, Petkanas said.
Kannalife would then consider an IPO, a bold move at a time when biotechnology stocks are reeling from political criticism of drug prices. The Nasdaq Biotechnology index had fallen nearly 24 percent this year through Wednesday’s close.
More generally, a tepid U.S. market for IPOs has raised just $253 million so far this year, compared with $4 billion in the corresponding year-earlier period.
“We’re throwing the ball in the air right now, because the dynamics of the market have changed considerably in the last six months,” said Petkanas.
As well as its HE drug, Kannalife is conducting a feasibility study into the development of a preventative treatment, also derived from synthetic cannabis, for chronic traumatic encephalopathy (CTE).
CTE is a brain condition resulting from repeated blows to the head, which is poorly understood and has no existing treatment. A sure-shot diagnosis can only be made after death.
For this study, Kannalife has procured a permit from the U.S. Drug Enforcement Administration to import a limited amount of pure cannabidiol, a non-psychoactive component of the Cannabis sativa plant.
John Kagia, director of industry analytics at cannabis-focused data firm New Frontier, said the drug had significant potential due to the extent to which CTE has become an issue for football players and the military.
“The successful deployment of cannabis within these two communities could be a watershed moment in the way the general population thinks about the therapeutic applications of marijuana,” he said. (Reporting by Natalie Grover in Bengaluru; Editing by Robin Paxton)
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
NEW YORK, Feb. 16, 2016 — Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of its novel cannabidiol-like therapeutic compounds to treat neurodegenerative and oxidative stress-related diseases. The publication titled, “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability” has been published in American Chemical Society’s ACS Medicinal Chemistry Letters.
Dean Petkanas, Chief Executive Officer of Kannalife stated, “My greatest appreciation goes out to all the scientists and professionals credited and cited for the body of science behind the publication of KLS-13019, for their steadfast efforts and deep rooted belief in the work we are performing at Kannalife. I also want to thank the American Chemical Society for acceptance of this publication and the peer review scientists who took the time to give their feedback and analysis of the science behind KLS-13019.”
About American Chemical Society – ACS Publications
The American Chemical Society (“ACS”) is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. The ACS was founded in 1876 and committed to sharing its professional work with a public audience. It began publishing its flagship journal, the Journal of the American Chemical Society (JACS), in April 1879. The ACS has over 160,000 members, more than 83 million ACS Journal article downloads, and published more than 42 million chemical abstracts. For more information, visit: www.acs.org – “Improving People’s Lives Through the Transforming Power of Chemistry.”
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com
Kannalife Sciences Announces Publication of “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, With Improved Potency, Safety and Permeability”
NEW YORK, Feb. 16, 2016 — Kannalife Sciences, Inc. (“Kannalife”), a Phyto-Medical Company, is pleased to announce the publication of the body of science behind KLS-13019, one of its novel cannabidiol-like therapeutic compounds to treat neurodegenerative and oxidative stress-related diseases. The publication titled, “Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability” has been published in American Chemical Society’s ACS Medicinal Chemistry Letters.
Dean Petkanas, Chief Executive Officer of Kannalife stated, “My greatest appreciation goes out to all the scientists and professionals credited and cited for the body of science behind the publication of KLS-13019, for their steadfast efforts and deep rooted belief in the work we are performing at Kannalife. I also want to thank the American Chemical Society for acceptance of this publication and the peer review scientists who took the time to give their feedback and analysis of the science behind KLS-13019.”
About American Chemical Society – ACS Publications
The American Chemical Society (“ACS”) is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. The ACS was founded in 1876 and committed to sharing its professional work with a public audience. It began publishing its flagship journal, the Journal of the American Chemical Society (JACS), in April 1879. The ACS has over 160,000 members, more than 83 million ACS Journal article downloads, and published more than 42 million chemical abstracts. For more information, visit: www.acs.org – “Improving People’s Lives Through the Transforming Power of Chemistry.”
About Kannalife Sciences, Inc. – A Phyto-Medical Company™
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com
The Ghosts of the NFL (The Players’ Tribune)
“CTE is the NFL’s industrial disease … Unless the NFL makes a serious shift, it’s very difficult to believe that it will continue to be the most popular sports league in America.”
Former lineman Marvin Washington on why the future of the NFL may be tied to CTE research.
Marvin Washington writes on #ThePlayersTribune about his 11 year career, experience with concussions, Dr. Bennet #Omalu’s discovery of #CTE and the work at #Kannalife Sciences to find a #treatment using #cannabinoids
“CTE is the NFL’s industrial disease … Unless the NFL makes a serious shift, it’s very difficult to believe that it will continue to be the most popular sports league in America.”
Former lineman Marvin Washington on why the future of the NFL may be tied to CTE research.
Marvin Washington writes on #ThePlayersTribune about his 11 year career, experience with concussions, Dr. Bennet #Omalu’s discovery of #CTE and the work at #Kannalife Sciences to find a #treatment using #cannabinoids
‘Concussion’ doctor aiding marijuana-based research company
The doctor portrayed in the upcoming football movie “Concussion” is on the board of a company looking for a marijuana-based treatment for head injuries.
Bennet Omalu was recently named to the scientific advisory board of Kannalife Sciences, which has been developing marijuana-based products to treat the effects of concussions.
Omalu conducted the autopsy on former Steelers center Mike Webster that led to the discovery of chronic traumatic encephalopathy or CTE. The concussion-related disease has been found in the brains of a number of former NFL players during autopsies.
Kannalife CEO Dean Petkanas said the company is working on a feasibility study for a product that would treat concussions using cannabinoids as an active pharmaceutical ingredient. Omalu, slated to be on the board through 2016, will be involved in oversight of the clinical tracking protocols for the study.
The doctor portrayed in the upcoming football movie “Concussion” is on the board of a company looking for a marijuana-based treatment for head injuries.
Bennet Omalu was recently named to the scientific advisory board of Kannalife Sciences, which has been developing marijuana-based products to treat the effects of concussions.
Omalu conducted the autopsy on former Steelers center Mike Webster that led to the discovery of chronic traumatic encephalopathy or CTE. The concussion-related disease has been found in the brains of a number of former NFL players during autopsies.
Kannalife CEO Dean Petkanas said the company is working on a feasibility study for a product that would treat concussions using cannabinoids as an active pharmaceutical ingredient. Omalu, slated to be on the board through 2016, will be involved in oversight of the clinical tracking protocols for the study.
Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019
NEW YORK, Aug. 11, 2015 — Kannalife Sciences, Inc., a Phyto-Medical Company, describes orphan drug opportunity for KLS-13019, a Novel Functionalized 1,3-Benzene Diol for the Treatment of Hepatic Encephalopathy recently published in PCT Patent WO2015/106108A2.
“Our pre-clinical studies using cannabidiol (CBD) as a positive control, side-by-side with KLS-13019 and other cannabidiol-like molecules of this class, reveals dramatic potency and safety improvements for this novel chemotype. Kannalife’s patent application further describes the novel chemotype useful as neuroprotective agents in the treatment of diseases associated with hepatic encephalopathy. KLS-13019 demonstrated improved oral bioavailability and CNS penetration relative to CBD and bodes well for its ability to penetrate the blood brain barrier, ameliorate brain toxicities associated with HE, and address unmet medical needs,” stated Dean Petkanas, CEO of Kannalife.
In 2010, Salix Pharmaceuticals’ drug Xifaxan® (Rifixamin), received priority review under FDA’s new drug application process and was granted orphan designation status for their HE indication. Priority review is designed to expedite programs on new drug applications for serious conditions. Orphan status grants seven years exclusivity. It is estimated that there are 1.5 million sufferers of hepatic encephalopathy (HE) in the US, of which, approximately 200,000 patients suffer from overt hepatic encephalopathy (Grade 3), representing an orphan drug opportunity for a novel drug in use.
Petkanas further stated, “In 2010 we believed there was an opportunity to build upon the promising preclinical findings with CBD in HE and design a novel cannabidiol-like therapeutic agent that would have benefits in terms of therapeutic index and delivery by the oral route. Developing our New Chemical Entity via the orphan status pathway will provide advantages in terms of reduced development cost and greater exclusivity in the marketplace.”
According to a report by Credit Suisse, Xifaxan® sales to treat Hepatic Encephalopathy accounted for roughly 70% of total Salix sales and is estimated to deliver approximately $900 million in 2015 with estimates driving towards $1.4 billion by 2018.
For more information on Hepatic Encephalopathy visit:
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com
NEW YORK, Aug. 11, 2015 — Kannalife Sciences, Inc., a Phyto-Medical Company, describes orphan drug opportunity for KLS-13019, a Novel Functionalized 1,3-Benzene Diol for the Treatment of Hepatic Encephalopathy recently published in PCT Patent WO2015/106108A2.
“Our pre-clinical studies using cannabidiol (CBD) as a positive control, side-by-side with KLS-13019 and other cannabidiol-like molecules of this class, reveals dramatic potency and safety improvements for this novel chemotype. Kannalife’s patent application further describes the novel chemotype useful as neuroprotective agents in the treatment of diseases associated with hepatic encephalopathy. KLS-13019 demonstrated improved oral bioavailability and CNS penetration relative to CBD and bodes well for its ability to penetrate the blood brain barrier, ameliorate brain toxicities associated with HE, and address unmet medical needs,” stated Dean Petkanas, CEO of Kannalife.
In 2010, Salix Pharmaceuticals’ drug Xifaxan® (Rifixamin), received priority review under FDA’s new drug application process and was granted orphan designation status for their HE indication. Priority review is designed to expedite programs on new drug applications for serious conditions. Orphan status grants seven years exclusivity. It is estimated that there are 1.5 million sufferers of hepatic encephalopathy (HE) in the US, of which, approximately 200,000 patients suffer from overt hepatic encephalopathy (Grade 3), representing an orphan drug opportunity for a novel drug in use.
Petkanas further stated, “In 2010 we believed there was an opportunity to build upon the promising preclinical findings with CBD in HE and design a novel cannabidiol-like therapeutic agent that would have benefits in terms of therapeutic index and delivery by the oral route. Developing our New Chemical Entity via the orphan status pathway will provide advantages in terms of reduced development cost and greater exclusivity in the marketplace.”
According to a report by Credit Suisse, Xifaxan® sales to treat Hepatic Encephalopathy accounted for roughly 70% of total Salix sales and is estimated to deliver approximately $900 million in 2015 with estimates driving towards $1.4 billion by 2018.
For more information on Hepatic Encephalopathy visit:
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.kannalife.com
Kannalife Sciences Announces Publication of Its Global PCT Patent Covering Cannabidiol-like Neuroprotective Agents
NEW YORK, Aug. 6, 2015 — Kannalife Sciences, Inc., a Phyto-Medical Company, announced the publication of its global WIPO/PCT Patent WO2015/106108A2 – ‘Novel Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy’.
It is widely understood that hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE) are associated with free radical mediated stress in neurons. Treatments that ameliorate this neural damage will demonstrate improvements in cognitive function, learning, and memory. Cannabidiol (CBD) has potential in treating oxidative stress but has limitations in terms of safety and pharmacokinetics, making the safe delivery of an efficacious dose problematic. KLS-13019 improves upon CBD in terms of neuroprotective potency and safety in hippocampal cultures, and dramatic improvements to oral bioavailability in rats.
Free radical mediated stress and oxidative stress is also known to contribute to additional pathological conditions, including, but not limited to epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Hence, compounds, such as Kannalife’s novel therapeutic agent KLS-13019, may be capable of acting as neuroprotective agents and useful for the treatment of epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
Kannalife CEO, Dean Petkanas, stated, “We believe our recently published PCT patent application will result in issuance of patents internationally, which will provide exclusivity until at least 2034. This is a testament to hard work, dedication, and professionalism of the Kannalife team in the field of cannabinoid based therapeutics. We are particularly proud of this accomplishment in light of the pioneering research in this field by notable scientists such as Julius Axelrod, Raphael Mechoulam, and Alexandros Makriyiannis.”
About KannaLife Sciences, Inc.
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.Kannalife.com.
NEW YORK, Aug. 6, 2015 — Kannalife Sciences, Inc., a Phyto-Medical Company, announced the publication of its global WIPO/PCT Patent WO2015/106108A2 – ‘Novel Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy’.
It is widely understood that hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE) are associated with free radical mediated stress in neurons. Treatments that ameliorate this neural damage will demonstrate improvements in cognitive function, learning, and memory. Cannabidiol (CBD) has potential in treating oxidative stress but has limitations in terms of safety and pharmacokinetics, making the safe delivery of an efficacious dose problematic. KLS-13019 improves upon CBD in terms of neuroprotective potency and safety in hippocampal cultures, and dramatic improvements to oral bioavailability in rats.
Free radical mediated stress and oxidative stress is also known to contribute to additional pathological conditions, including, but not limited to epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). Hence, compounds, such as Kannalife’s novel therapeutic agent KLS-13019, may be capable of acting as neuroprotective agents and useful for the treatment of epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
Kannalife CEO, Dean Petkanas, stated, “We believe our recently published PCT patent application will result in issuance of patents internationally, which will provide exclusivity until at least 2034. This is a testament to hard work, dedication, and professionalism of the Kannalife team in the field of cannabinoid based therapeutics. We are particularly proud of this accomplishment in light of the pioneering research in this field by notable scientists such as Julius Axelrod, Raphael Mechoulam, and Alexandros Makriyiannis.”
About KannaLife Sciences, Inc.
Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.Kannalife.com.
CNN’s WEED3 with Dr. Sanjay Gupta features Kannalife and CEO Dean Petkanas
Dr. Sanjay Gupta interviews Kannalife Sciences CEO Dean Petkanas and the exclusive license to the US Government’s patent on Cannabis. “Cannabinoids as Antioxidants and Neuroprotectants”.
Kannalife is working on two (2) distinct disease indications that effect the Brain. One is a brain-liver disease called Hepatic Encephalopathy (HE) and the second is a concussion related traumatic brain injury called Chronic Traumatic Encephalopathy (CTE).
Dr. Sanjay Gupta interviews Kannalife Sciences CEO Dean Petkanas and the exclusive license to the US Government’s patent on Cannabis. “Cannabinoids as Antioxidants and Neuroprotectants”.
Kannalife is working on two (2) distinct disease indications that effect the Brain. One is a brain-liver disease called Hepatic Encephalopathy (HE) and the second is a concussion related traumatic brain injury called Chronic Traumatic Encephalopathy (CTE).
Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board
Huntington, NY – Kannalife Sciences, Inc. (“Kannalife”) announces that Dr. Bennet Omalu, MD has joined its Scientific Advisory Board to assist the Company in the advancement of its research and development efforts towards the use of cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy (CTE). Dr. Omalu is the forensic pathologist responsible for conducting the full autopsy of Mike Webster, the deceased NFL Hall of Fame center for the Pittsburgh Steelers. It was through his examination of Mike Webster that led to his discovery of CTE.
In August of 2014, Kannalife Sciences signed a license agreement with the National Institutes of Heath (NIH) for U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”) to develop a treatment for CTE using cannabinoids. Cannabinoids are any of a group of related compounds that include the non-psychoactive Cannabidiol as well as Tetrahydrocannabinol; the active constituent of cannabis (marijuana).
Dr. Omalu stated, “I am humbled and honored by the invitation to join the medical advisory board of Kannalife. Together we can make great strides in the diagnosis and management of CTE and other neurodegenerative diseases in living subjects.”
Kannalife’s CEO, Dean Petkanas, added, “It is with great pleasure that we have the opportunity to work with Dr. Omalu on the therapeutic side of Chronic Traumatic Encephalopathy. We recognize his commitment to helping people combat disease and applaud his remarkable career and body of knowledge in this space. I believe with Dr. Omalu’s contribution towards improving our visibility into the pathology of this disease, we will hopefully bring forth a novel therapeutic drug into the market and make a difference in the lives of many who suffer with CTE.”
Acute, late stage CTE is a form of encephalopathy, resulting in the accumulation of tau protein that is marked by a sudden and rapidly progressive neuro-degeneration and atrophy of the hippocampus, entorhinal cortex and amygdala regions in the human brain. Unfortunately, early signs are difficult to detect and rapid succession of the disease leads to suicidal death. Postmortem diagnosis typically reveals the extent of the disease.
CTE has been most commonly found in professional athletes participating in American football, ice hockey, professional wrestling and other contact and collision sports who have experienced repetitive brain trauma and concussive head injury. It has also been found in combat military men and women exposed to a blast or a concussive injury. Individuals with CTE may show symptoms of dementia, such as memory loss, aggression, confusion and depression, which generally appear years or many decades after the trauma.
About Dr. Bennet Omalu, MD
Dr. Omalu was the first to identify, describe and name Chronic Traumatic Encephalopathy (CTE) as a disease entity in football players and wrestlers. He is currently the Forensic Pathologist/Neuropathologist of San Joaquin County, California, and is the President and Medical Director of Bennet Omalu Pathology. He also serves as a Clinical Associate Professor at the UC, Davis Medical Center, Department of Medical Pathology and Laboratory Medicine.
Dr. Omalu has testified twice before the United States Congress and has provided hundreds of testimonies as an expert witness in federal courts and state courts across the United States. Dr. Omalu is the focal point of the highly acclaimed PBS’ FRONTLINE documentary called “League of Denial”.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions.
For more information, please visit:
Huntington, NY – Kannalife Sciences, Inc. (“Kannalife”) announces that Dr. Bennet Omalu, MD has joined its Scientific Advisory Board to assist the Company in the advancement of its research and development efforts towards the use of cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy (CTE). Dr. Omalu is the forensic pathologist responsible for conducting the full autopsy of Mike Webster, the deceased NFL Hall of Fame center for the Pittsburgh Steelers. It was through his examination of Mike Webster that led to his discovery of CTE.
In August of 2014, Kannalife Sciences signed a license agreement with the National Institutes of Heath (NIH) for U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”) to develop a treatment for CTE using cannabinoids. Cannabinoids are any of a group of related compounds that include the non-psychoactive Cannabidiol as well as Tetrahydrocannabinol; the active constituent of cannabis (marijuana).
Dr. Omalu stated, “I am humbled and honored by the invitation to join the medical advisory board of Kannalife. Together we can make great strides in the diagnosis and management of CTE and other neurodegenerative diseases in living subjects.”
Kannalife’s CEO, Dean Petkanas, added, “It is with great pleasure that we have the opportunity to work with Dr. Omalu on the therapeutic side of Chronic Traumatic Encephalopathy. We recognize his commitment to helping people combat disease and applaud his remarkable career and body of knowledge in this space. I believe with Dr. Omalu’s contribution towards improving our visibility into the pathology of this disease, we will hopefully bring forth a novel therapeutic drug into the market and make a difference in the lives of many who suffer with CTE.”
Acute, late stage CTE is a form of encephalopathy, resulting in the accumulation of tau protein that is marked by a sudden and rapidly progressive neuro-degeneration and atrophy of the hippocampus, entorhinal cortex and amygdala regions in the human brain. Unfortunately, early signs are difficult to detect and rapid succession of the disease leads to suicidal death. Postmortem diagnosis typically reveals the extent of the disease.
CTE has been most commonly found in professional athletes participating in American football, ice hockey, professional wrestling and other contact and collision sports who have experienced repetitive brain trauma and concussive head injury. It has also been found in combat military men and women exposed to a blast or a concussive injury. Individuals with CTE may show symptoms of dementia, such as memory loss, aggression, confusion and depression, which generally appear years or many decades after the trauma.
About Dr. Bennet Omalu, MD
Dr. Omalu was the first to identify, describe and name Chronic Traumatic Encephalopathy (CTE) as a disease entity in football players and wrestlers. He is currently the Forensic Pathologist/Neuropathologist of San Joaquin County, California, and is the President and Medical Director of Bennet Omalu Pathology. He also serves as a Clinical Associate Professor at the UC, Davis Medical Center, Department of Medical Pathology and Laboratory Medicine.
Dr. Omalu has testified twice before the United States Congress and has provided hundreds of testimonies as an expert witness in federal courts and state courts across the United States. Dr. Omalu is the focal point of the highly acclaimed PBS’ FRONTLINE documentary called “League of Denial”.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions.
For more information, please visit:
Kannalife Files PCT Patent Application for Novel Treatments for Neurodegenerative Disorders
Huntington, NY (January 23, 2015) Kannalife Sciences, Inc. (“Kannalife”) announces that it has filed a non-provisional patent application entitled: “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.” The patent describes a family of candidate molecules which are safer and more effective than cannabidiol in an in vitro assay of neuroprotection. The assay evaluates the ability of a test agent to protect hippocampal neurons from oxidative stress induced by ammonia and ethanol at clinically relevant concentrations. In addition to demonstrating favorable in vitro effects, the current lead molecule also shows significant improvement in absorption of the drug and plasma and brain drug levels after oral administration, as compared to cannabidiol.
Cannabidiol (“CBD”) is a non-psychoactive natural product from C. sativa that has been shown by researchers at Hadassah-Hebrew University Medical School and Hebrew University to be effective in two mouse models of HE (Thioacetam¬ide induced liver damage: Y. Avhraham, et al. Br. J. Pharmacol. 2011, 162, 1650-1658; Bile duct ligation induced liver damage: I. Magen, et al. J. Hepatol. 2009, 51, 528-534) at a dose of 5 mg/kg ip. CBD treated animals exhibited improvements in both liver and brain function compared to untreated control animals. Comparative studies with our lead compound versus CBD are in progress and will be reported in due course.
Kannalife’s current lead molecule may be useful in the treatment of Overt Hepatic Encephalopathy (“OHE”), considered a late stage refractory form of HE with a patient population of approximately 200,000, classifying it as an orphan disease. Hepatic encephalopathy (“HE”) is a serious neurological disorder that can occur in patients with cirrhosis or liver failure.
“Filing of this new PCT patent application represents an important milestone for our company in generating new intellectual property that advances the field beyond natural cannabinoid-based neuroprotectives. It fits in with our business plan to broaden the armament of drug candidates to address unmet medical needs in the areas of neuroprotection, neurogenesis, and oxidative stress,” stated Dean Petkanas, CEO of Kannalife Sciences, Inc.
Kannalife Sciences holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”).
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions.
For more information, please visit:
www.kannalife.com
Huntington, NY (January 23, 2015) Kannalife Sciences, Inc. (“Kannalife”) announces that it has filed a non-provisional patent application entitled: “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.” The patent describes a family of candidate molecules which are safer and more effective than cannabidiol in an in vitro assay of neuroprotection. The assay evaluates the ability of a test agent to protect hippocampal neurons from oxidative stress induced by ammonia and ethanol at clinically relevant concentrations. In addition to demonstrating favorable in vitro effects, the current lead molecule also shows significant improvement in absorption of the drug and plasma and brain drug levels after oral administration, as compared to cannabidiol.
Cannabidiol (“CBD”) is a non-psychoactive natural product from C. sativa that has been shown by researchers at Hadassah-Hebrew University Medical School and Hebrew University to be effective in two mouse models of HE (Thioacetam¬ide induced liver damage: Y. Avhraham, et al. Br. J. Pharmacol. 2011, 162, 1650-1658; Bile duct ligation induced liver damage: I. Magen, et al. J. Hepatol. 2009, 51, 528-534) at a dose of 5 mg/kg ip. CBD treated animals exhibited improvements in both liver and brain function compared to untreated control animals. Comparative studies with our lead compound versus CBD are in progress and will be reported in due course.
Kannalife’s current lead molecule may be useful in the treatment of Overt Hepatic Encephalopathy (“OHE”), considered a late stage refractory form of HE with a patient population of approximately 200,000, classifying it as an orphan disease. Hepatic encephalopathy (“HE”) is a serious neurological disorder that can occur in patients with cirrhosis or liver failure.
“Filing of this new PCT patent application represents an important milestone for our company in generating new intellectual property that advances the field beyond natural cannabinoid-based neuroprotectives. It fits in with our business plan to broaden the armament of drug candidates to address unmet medical needs in the areas of neuroprotection, neurogenesis, and oxidative stress,” stated Dean Petkanas, CEO of Kannalife Sciences, Inc.
Kannalife Sciences holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”).
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions.
For more information, please visit:
www.kannalife.com
Introducing Kannalife™
Kannalife mention in VOX – Marijuana’s medical use is illegal under federal law. It’s also patented by the feds.
Excertt
“…marijuana a schedule 1 drug, a controlled substance that has some potential for abuse and no medical value. But the federal government also owns, through the US Department of Health and Human Services (HHS), a patent that appears to acknowledge marijuana can act as medicine.
The potential contradiction is a big deal for supporters of marijuana legalization and medical marijuana. If the federal government thinks marijuana has some medical value, then the drug should be rescheduled to a lower legal restriction — one that could give state governments the ability to implement relaxed marijuana laws without as much federal interference.
The federal government’s patent (US6630507), issued to HHS in 2003, claims the legal rights to several non-psychoactive components — meaning compounds that don’t get someone high — in marijuana, including CBD (cannabidiol), which made headlines recently for its ability to treat seizures in children. The patent claims the cannabinoids can act as antioxidants and neuroprotectants that are useful for treating ischemic, age-related, inflammatory, and autoimmune diseases; Alzheimer’s disease; Parkinson’s disease; and HIV dementia.
The patent allows for further research into the cannabinoids, and it lets companies apply for licenses they could use to develop drugs based on the components.
The National Institutes of Health (NIH) previously granted an exclusive license to the company Kannalife to develop drugs based on these non-psychoactive compounds for the treatment of brain damage caused by a diseased liver. Before the drugs reach the market, the company will have to conduct clinical trials and obtain Food and Drug Administration (FDA) approval.”
“…marijuana a schedule 1 drug, a controlled substance that has some potential for abuse and no medical value. But the federal government also owns, through the US Department of Health and Human Services (HHS), a patent that appears to acknowledge marijuana can act as medicine.
The potential contradiction is a big deal for supporters of marijuana legalization and medical marijuana. If the federal government thinks marijuana has some medical value, then the drug should be rescheduled to a lower legal restriction — one that could give state governments the ability to implement relaxed marijuana laws without as much federal interference.
The federal government’s patent (US6630507), issued to HHS in 2003, claims the legal rights to several non-psychoactive components — meaning compounds that don’t get someone high — in marijuana, including CBD (cannabidiol), which made headlines recently for its ability to treat seizures in children. The patent claims the cannabinoids can act as antioxidants and neuroprotectants that are useful for treating ischemic, age-related, inflammatory, and autoimmune diseases; Alzheimer’s disease; Parkinson’s disease; and HIV dementia.
The patent allows for further research into the cannabinoids, and it lets companies apply for licenses they could use to develop drugs based on the components.
The National Institutes of Health (NIH) previously granted an exclusive license to the company Kannalife to develop drugs based on these non-psychoactive compounds for the treatment of brain damage caused by a diseased liver. Before the drugs reach the market, the company will have to conduct clinical trials and obtain Food and Drug Administration (FDA) approval.”
Dean Petkanas on Fox Business’ Varney & Co. with host Charles Payne
Condition at Center of NFL Lawsuit Targeted by Medical Marijuana Company
A plant-based pharmaceutical company is working on developing a medical marijuana treatment for chronic traumatic encephalopathy (CTE), a degenerative disease that affects people—particularly athletes—who have suffered repeated head trauma.
We’re really looking at the athlete brain,” Thoma Kikis, the company’s chief visionary officer, told FoxNews.com. Their goal is to create a treatment that is both preventative and therapeutic for those already diagnosed with CTE.
Dean Petkanas, the chief executive of KannaLife Sciences, expects the federal government to pave the way for medical marijuana within two years, he told Varney & Co. on Monday.
Condition at Center of NFL Lawsuit Targeted by Medical Marijuana Company
A plant-based pharmaceutical company is working on developing a medical marijuana treatment for chronic traumatic encephalopathy (CTE), a degenerative disease that affects people—particularly athletes—who have suffered repeated head trauma.
We’re really looking at the athlete brain,” Thoma Kikis, the company’s chief visionary officer, told FoxNews.com. Their goal is to create a treatment that is both preventative and therapeutic for those already diagnosed with CTE.
Dean Petkanas, the chief executive of KannaLife Sciences, expects the federal government to pave the way for medical marijuana within two years, he told Varney & Co. on Monday.
Kannalife Sciences, Inc. Signs New License Agreement with National Institutes of Health (NIH) for Treatment of Chronic Traumatic Encephalopathy
NEW YORK, Aug. 4, 2014 — Kannalife Sciences, Inc. (“Kannalife”) Signs New License Agreement With National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). This new license agreement provides the rights for the Company’s development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, as FDA approved drugs, for the treatment of Chronic Traumatic Encephalopathy (CTE) in humans. The ‘507 Patent includes among other things, claims directed to a method of treating diseases caused by oxidative stress by administering a therapeutically effective amount of a non-psychoactive cannabinoid that has substantially no binding to the NMDA receptor. Cannabinoids are any of a group of related compounds that include the non-psychoactive Cannabidiol as well as Tetrahydrocannabinol; the active constituent of cannabis (marijuana).
Dean Petkanas, Founder and CEO of Kannalife Sciences, Inc. stated, “We are very pleased to have this opportunity to add an additional license through NIH-OTT under the ‘507 Patent’ for the furtherance of research and development of target therapeutics to treat head trauma and, more specifically Chronic Traumatic Encephalopathy (CTE). This disease has perplexed neurologists and the scientific community for well over two decades and recently caused U.S. District Court Judge Anita B. Brody to reject the preliminary approval of a $765 million settlement of NFL concussion claims, fearing it may not be enough to cover 20,000 retired players. We have committed ourselves towards researching and developing cannabinoid based therapeutics that can provide for preventative, curative and quality of life improvement for patients suffering with rare forms of encephalopathy. We can now focus our efforts on CTE alongside Hepatic Encephalopathy (HE) as our early pre-clinical work on HE is pointing towards advanced neuroprotection. We hope our early efforts on CTE will meet the same level of success as our on-going research and development regarding HE.”
Not unlike Hepatic Encephalopathy, CTE is a neuro-degenerative disease of the brain and is associated with repeated head traumas like concussions. CTE is a form of encephalopathy that is a progressive neuro-degenerative disease, which can only be definitively diagnosed postmortem, in individuals with a history of multiple concussions and other forms of head injury. CTE has been most commonly found in professional athletes participating in American football, ice hockey, professional wrestling and other contact sports who have experienced repetitive brain trauma. It has also been found in soldiers exposed to a blast or a concussive injury, in both cases resulting in characteristic degeneration of brain tissue and the accumulation of tau protein. Individuals with CTE may show symptoms of dementia, such as memory loss, aggression, confusion and depression, which generally appear years or many decades after the trauma.
About the NIH Office of Technology Transfer (NIH-OTT):
NIH-OTT manages the patenting and licensing of a wide range of inventions made by scientists working for the NIH, FDA and CDC intramural research programs as mandated by the Federal Technology Transfer Act.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.
NEW YORK, Aug. 4, 2014 — Kannalife Sciences, Inc. (“Kannalife”) Signs New License Agreement With National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). This new license agreement provides the rights for the Company’s development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, as FDA approved drugs, for the treatment of Chronic Traumatic Encephalopathy (CTE) in humans. The ‘507 Patent includes among other things, claims directed to a method of treating diseases caused by oxidative stress by administering a therapeutically effective amount of a non-psychoactive cannabinoid that has substantially no binding to the NMDA receptor. Cannabinoids are any of a group of related compounds that include the non-psychoactive Cannabidiol as well as Tetrahydrocannabinol; the active constituent of cannabis (marijuana).
Dean Petkanas, Founder and CEO of Kannalife Sciences, Inc. stated, “We are very pleased to have this opportunity to add an additional license through NIH-OTT under the ‘507 Patent’ for the furtherance of research and development of target therapeutics to treat head trauma and, more specifically Chronic Traumatic Encephalopathy (CTE). This disease has perplexed neurologists and the scientific community for well over two decades and recently caused U.S. District Court Judge Anita B. Brody to reject the preliminary approval of a $765 million settlement of NFL concussion claims, fearing it may not be enough to cover 20,000 retired players. We have committed ourselves towards researching and developing cannabinoid based therapeutics that can provide for preventative, curative and quality of life improvement for patients suffering with rare forms of encephalopathy. We can now focus our efforts on CTE alongside Hepatic Encephalopathy (HE) as our early pre-clinical work on HE is pointing towards advanced neuroprotection. We hope our early efforts on CTE will meet the same level of success as our on-going research and development regarding HE.”
Not unlike Hepatic Encephalopathy, CTE is a neuro-degenerative disease of the brain and is associated with repeated head traumas like concussions. CTE is a form of encephalopathy that is a progressive neuro-degenerative disease, which can only be definitively diagnosed postmortem, in individuals with a history of multiple concussions and other forms of head injury. CTE has been most commonly found in professional athletes participating in American football, ice hockey, professional wrestling and other contact sports who have experienced repetitive brain trauma. It has also been found in soldiers exposed to a blast or a concussive injury, in both cases resulting in characteristic degeneration of brain tissue and the accumulation of tau protein. Individuals with CTE may show symptoms of dementia, such as memory loss, aggression, confusion and depression, which generally appear years or many decades after the trauma.
About the NIH Office of Technology Transfer (NIH-OTT):
NIH-OTT manages the patenting and licensing of a wide range of inventions made by scientists working for the NIH, FDA and CDC intramural research programs as mandated by the Federal Technology Transfer Act.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.
Thoma Kikis on Bloomberg TV Street Smart with host Trish Regan
Aug. 4 –- Kannalife Sciences Founder Thoma Kikis and Leafly CEO Brendan Kennedy discuss using cannabinoid–based therapeutics to treat chronic traumatic encephalopathy and Leafly’s New York Times marijuana ad. They speak on “Street Smart.” (Source: Bloomberg)
Aug. 4 –- Kannalife Sciences Founder Thoma Kikis and Leafly CEO Brendan Kennedy discuss using cannabinoid–based therapeutics to treat chronic traumatic encephalopathy and Leafly’s New York Times marijuana ad. They speak on “Street Smart.” (Source: Bloomberg)
Thoma Kikis on Bloomberg TV “Taking Stock” with host Pimm Fox
July 8 (Bloomberg) — Thoma Kikis, co-founder of KannaLife Sciences, discusses the regulation of cannabis and Cannabinoid Therapeutics with Pimm Fox on “Taking Stock.” (Source: Bloomberg)
July 8 (Bloomberg) — Thoma Kikis, co-founder of KannaLife Sciences, discusses the regulation of cannabis and Cannabinoid Therapeutics with Pimm Fox on “Taking Stock.” (Source: Bloomberg)
Kannalife Sciences, Inc. and Kannaway, LLC Sign Long Term Sales, Marketing and Product Development Agreement
WEST HILLS, N.Y., March 31, 2014 — Kannalife Sciences, Inc. (“Kannalife”) and Kannaway LLC (“Kannaway”), have entered into a five year sales, marketing and product development agreement (the “Agreement”).
Kannaway is the only network marketing company in the U.S. currently specializing in the sales of hemp based botanical products. Since its inception in January 2014, Kannaway has become one of the fastest growing sales marketing companies in U.S. history, having built a network sales force and subscriber base in excess of 40,000 professionals within the first three months of its existence (the “Kannaway Network”).
Under the Agreement, Kannalife will be developing and branding novel phyto-medical and naturopathic products, as well as certifying additional products being sold through the Kannaway Network.
Dean Petkanas, CEO of Kannalife stated, “We have been entrenched in product research and development for the last nine months, advancing our efforts towards the creation of natural cannabinoid based medicaments and synthetic cannabinoid like molecules which have improved drug like properties. The timing for entering into this Agreement with Kannaway couldn’t be better. We now have this once in a lifetime opportunity to be side by side with the most dynamic sales force in the industry, pressed right up at the forefront of the high demand, consumer products driven market for hemp and cannabinoid consumables and body care products.”
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed as neuroprotectants, immuno-modulators and reduce oxidative stress. Kannalife Sciences currently holds an exclusive license with National Institutes of Health — Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (“HE”). HE is an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain and the liver.
For more information, please visit Kannalife’s website at: www.kannalife.com
About Kannaway, LLC, is a network sales and marketing company specializing in the sales and marketing of hemp based botanical products. Kannaway currently hosts weekly on-line sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp based botanical products. Kannaway currently has over 40,000 marketing professionals in its network.
For more information, please visit Kannaway’s website at: www.kannaway.com
WEST HILLS, N.Y., March 31, 2014 — Kannalife Sciences, Inc. (“Kannalife”) and Kannaway LLC (“Kannaway”), have entered into a five year sales, marketing and product development agreement (the “Agreement”).
Kannaway is the only network marketing company in the U.S. currently specializing in the sales of hemp based botanical products. Since its inception in January 2014, Kannaway has become one of the fastest growing sales marketing companies in U.S. history, having built a network sales force and subscriber base in excess of 40,000 professionals within the first three months of its existence (the “Kannaway Network”).
Under the Agreement, Kannalife will be developing and branding novel phyto-medical and naturopathic products, as well as certifying additional products being sold through the Kannaway Network.
Dean Petkanas, CEO of Kannalife stated, “We have been entrenched in product research and development for the last nine months, advancing our efforts towards the creation of natural cannabinoid based medicaments and synthetic cannabinoid like molecules which have improved drug like properties. The timing for entering into this Agreement with Kannaway couldn’t be better. We now have this once in a lifetime opportunity to be side by side with the most dynamic sales force in the industry, pressed right up at the forefront of the high demand, consumer products driven market for hemp and cannabinoid consumables and body care products.”
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed as neuroprotectants, immuno-modulators and reduce oxidative stress. Kannalife Sciences currently holds an exclusive license with National Institutes of Health — Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (“HE”). HE is an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain and the liver.
For more information, please visit Kannalife’s website at: www.kannalife.com
About Kannaway, LLC, is a network sales and marketing company specializing in the sales and marketing of hemp based botanical products. Kannaway currently hosts weekly on-line sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp based botanical products. Kannaway currently has over 40,000 marketing professionals in its network.
For more information, please visit Kannaway’s website at: www.kannaway.com
Kannalife Sciences, Inc. Signs Materials Transfer and Testing Agreement with Baruch S. Blumberg Institute
WEST HILLS, N.Y., Dec. 20, 2013 – Kannalife Sciences, Inc. (“Kannalife”) announces that it has entered into a Materials Transfer and Testing Agreement with the Natural Product Discovery Institute (NPDI), a division of the Baruch S. Blumberg Institute (BSBI), to provide Kannalife with access to a collection of more than 100,000 extracts from plants, fungi, and bacteria, previously owned by Merck and donated to the Institute in 2011. The NPDI natural products library is regarded as one of the best collections of screen ready druggable libraries made from living organisms.
“Signing the MTA with the Institute is an outstanding opportunity for Kannalife to access targeted plant species for the identification of novel phytochemicals to treat the diseases of Chronic Traumatic Encephalopathy (CTE) and Hepatic Encephalopathy (HE). It fits in with our business plan to broaden the range of plant sources for addressing unmet medical needs in the areas of neuroprotection, neurogenesis, and oxidative stress. We are grateful for this excellent opportunity to work with a world class natural products discovery team at the Institute,” stated William Kinney, CSO of Kannalife Sciences, Inc.
About the Baruch S. Blumberg Institute
The Baruch S. Blumberg Institute, formerly the Institute for Hepatitis and Virus Research, is named in honor of the late Dr. Baruch S. Blumberg, who was awarded the 1976 Nobel Prize in Medicine for his discovery of the hepatitis B virus. Today, the Institute is the nation’s leading nonprofit research organization dedicated to hepatitis B and liver cancer worldwide. It was established by the Hepatitis B Foundation in 2003 to fulfill its research mission of finding a cure for hepatitis B in our lifetime.
The Institute supports programs dedicated to drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease, and liver cancer in an environment conducive to interaction, collaboration and focus. Its mission is to use discovery science to find new therapies and biomarkers for hepatitis B and liver cancer; to advance its research discoveries through traditional scholarship and educational opportunities; to nurture biotechnology; and to support broader discovery research programs in the Life Sciences. Through an unprecedented gift from Merck and Co., of its entire US Natural Products Library and the Schering-Plough Legacy Culture Collection, the Institute is also dedicated to making this remarkable resource available to the scientific community worldwide for natural product discovery in academic, pharmaceutical, agricultural, cosmetic, and nutritional projects.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed as neuroprotectants, immuno-modulators and reduce oxidative stress. Kannalife Sciences currently holds an exclusive license with National Institutes of Health — Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (“HE”). HE is an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain and the liver.
WEST HILLS, N.Y., Dec. 20, 2013 – Kannalife Sciences, Inc. (“Kannalife”) announces that it has entered into a Materials Transfer and Testing Agreement with the Natural Product Discovery Institute (NPDI), a division of the Baruch S. Blumberg Institute (BSBI), to provide Kannalife with access to a collection of more than 100,000 extracts from plants, fungi, and bacteria, previously owned by Merck and donated to the Institute in 2011. The NPDI natural products library is regarded as one of the best collections of screen ready druggable libraries made from living organisms.
“Signing the MTA with the Institute is an outstanding opportunity for Kannalife to access targeted plant species for the identification of novel phytochemicals to treat the diseases of Chronic Traumatic Encephalopathy (CTE) and Hepatic Encephalopathy (HE). It fits in with our business plan to broaden the range of plant sources for addressing unmet medical needs in the areas of neuroprotection, neurogenesis, and oxidative stress. We are grateful for this excellent opportunity to work with a world class natural products discovery team at the Institute,” stated William Kinney, CSO of Kannalife Sciences, Inc.
About the Baruch S. Blumberg Institute
The Baruch S. Blumberg Institute, formerly the Institute for Hepatitis and Virus Research, is named in honor of the late Dr. Baruch S. Blumberg, who was awarded the 1976 Nobel Prize in Medicine for his discovery of the hepatitis B virus. Today, the Institute is the nation’s leading nonprofit research organization dedicated to hepatitis B and liver cancer worldwide. It was established by the Hepatitis B Foundation in 2003 to fulfill its research mission of finding a cure for hepatitis B in our lifetime.
The Institute supports programs dedicated to drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease, and liver cancer in an environment conducive to interaction, collaboration and focus. Its mission is to use discovery science to find new therapies and biomarkers for hepatitis B and liver cancer; to advance its research discoveries through traditional scholarship and educational opportunities; to nurture biotechnology; and to support broader discovery research programs in the Life Sciences. Through an unprecedented gift from Merck and Co., of its entire US Natural Products Library and the Schering-Plough Legacy Culture Collection, the Institute is also dedicated to making this remarkable resource available to the scientific community worldwide for natural product discovery in academic, pharmaceutical, agricultural, cosmetic, and nutritional projects.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel therapeutic agents designed as neuroprotectants, immuno-modulators and reduce oxidative stress. Kannalife Sciences currently holds an exclusive license with National Institutes of Health — Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy (“HE”). HE is an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain and the liver.
Kannalife Sciences, Inc. Signs Research and Development Agreements With Advanced Neural Dynamics and IteraMed in the Discovery of Novel Neuroprotectants
NEW YORK, April 4, 2013 — Kannalife Sciences, Inc. (“Kannalife”) announces its collaboration with two experienced drug discovery organizations: Advanced Neural Dynamics and IteraMed. Kannalife will fund a new drug discovery project related to a laboratory validated phytochemical. The founding science is based on the licensed technology of Dr. A. J. Hampson at the Laboratory of Cellular and Molecular Regulation within the National Institutes of Mental Health. Dr. Hampson’s research has shown that this phytochemical is neuroprotective in cortical neuronal cultures exposed to toxic levels of glutamate or oxidative stress.
IteraMed and Advanced Neural Dynamics are located at the Pennsylvania Biotechnology Center. The Pennsylvania Biotechnology Center is a 112,000 square-foot biotechnology incubator in Doylestown, PA, houses one of the richest botanical collections in the world and is home to several and approximately thirty life sciences companies and several non-profit organizations. Dean Petkanas, CEO of Kannalife, stated: “This opportunity to begin our research and development program at the Pennsylvania Biotechnology Center, would not be possible without the support and financial backing of our investors, Medical Marijuana, Inc. and CannaVEST. The Pennsylvania Biotechnology Center has a scientifically rich environment in liver, neurological and botanical science, areas vital to Kannalife. Having this shared vision and support from MJNA and CannaVest is crucial to the long range research and development efforts planned between Kannalife, IteraMed and Advanced Neural Dynamics.”
About Advanced Neural Dyanamics (“AND”): AND is a drug discovery company founded in October 2008 by Dr. Douglas Brenneman, an expert in the pharmacology of small molecules and neuropeptides. AND’s focuses on developing novel small molecule neuroprotective therapeutics for the treatment of neurological diseases. AND’s neuroprotective drug discovery strategy is differentiated by the use of primary neural cultures derived from the central nervous system combined with biochemical, molecular and immunocytochemical methods that measure cellular responses to identify products that will be safer and more effective than currently approved therapies.
About IteraMed: IteraMed draws on the experience of experienced medicinal and pharmacology scientists with experience in a variety of disease areas including central nervous system disorders (depression, anxiety, neuroprotection), neuropathic pain, cardiovascular disease, oncology, and infection. IteraMed offers “value added” organic synthesis, medicinal chemistry consulting, and internal drug discovery. IteraMed supports a variety of industries including forensics testing laboratories, start-ups, and large pharmaceutical companies. For more information, please visit the company’s website at: www.iteramed.com
About Kannalife:
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). For more information, please visit the company’s website at: www.kannalife.com
NEW YORK, April 4, 2013 — Kannalife Sciences, Inc. (“Kannalife”) announces its collaboration with two experienced drug discovery organizations: Advanced Neural Dynamics and IteraMed. Kannalife will fund a new drug discovery project related to a laboratory validated phytochemical. The founding science is based on the licensed technology of Dr. A. J. Hampson at the Laboratory of Cellular and Molecular Regulation within the National Institutes of Mental Health. Dr. Hampson’s research has shown that this phytochemical is neuroprotective in cortical neuronal cultures exposed to toxic levels of glutamate or oxidative stress.
IteraMed and Advanced Neural Dynamics are located at the Pennsylvania Biotechnology Center. The Pennsylvania Biotechnology Center is a 112,000 square-foot biotechnology incubator in Doylestown, PA, houses one of the richest botanical collections in the world and is home to several and approximately thirty life sciences companies and several non-profit organizations. Dean Petkanas, CEO of Kannalife, stated: “This opportunity to begin our research and development program at the Pennsylvania Biotechnology Center, would not be possible without the support and financial backing of our investors, Medical Marijuana, Inc. and CannaVEST. The Pennsylvania Biotechnology Center has a scientifically rich environment in liver, neurological and botanical science, areas vital to Kannalife. Having this shared vision and support from MJNA and CannaVest is crucial to the long range research and development efforts planned between Kannalife, IteraMed and Advanced Neural Dynamics.”
About Advanced Neural Dyanamics (“AND”): AND is a drug discovery company founded in October 2008 by Dr. Douglas Brenneman, an expert in the pharmacology of small molecules and neuropeptides. AND’s focuses on developing novel small molecule neuroprotective therapeutics for the treatment of neurological diseases. AND’s neuroprotective drug discovery strategy is differentiated by the use of primary neural cultures derived from the central nervous system combined with biochemical, molecular and immunocytochemical methods that measure cellular responses to identify products that will be safer and more effective than currently approved therapies.
About IteraMed: IteraMed draws on the experience of experienced medicinal and pharmacology scientists with experience in a variety of disease areas including central nervous system disorders (depression, anxiety, neuroprotection), neuropathic pain, cardiovascular disease, oncology, and infection. IteraMed offers “value added” organic synthesis, medicinal chemistry consulting, and internal drug discovery. IteraMed supports a variety of industries including forensics testing laboratories, start-ups, and large pharmaceutical companies. For more information, please visit the company’s website at: www.iteramed.com
About Kannalife:
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). For more information, please visit the company’s website at: www.kannalife.com
Kannalife Sciences Announces $1.5M Series A Financing From Medical Marijuana Inc. (OTC:MJNA) And CannaVest Corp. (OTC:FCLS)
NEW YORK, March 7, 2013 — Kannalife Sciences, Inc. (“Kannalife”) the phyto-medical company that specializes in the research & development of pharmacological products derived from botanical sources, announced today the entry into Series A financing totaling $1.5 million.
The investment is led by and Medical Marijuana Inc. (OTC: MJNA) and CannaVest Corp. (OTC: FCLS).
“From Kannalife’s exclusive license with NIH to its years in development of standardization in packaging cannabis based products, lends a perfect fit for the Medical Marijuana Inc., family of companies. Particularly, the NIH exclusive license in our opinion is a true industry game changer. Our investment in Kannalife helps further build our pipeline of patented cannabinoid based medical products. In the very near future, it is patents such as this that we believe will determine a company’s future success in the cannabis based pharmaceutical industry.” – Michelle Sides, Chairman and Chief Operating Officer of Medical Marijuana Inc.
“The investments being made into Kannalife by CannaVest and MJNA go well beyond the actual dollars and cents.CannaVest and MJNA have paved highly sensible commercial inroads in the field of phyto-medics, and principally in the area of cannabinoid based medicaments. We are delighted to be part of the long range plans of both CannaVest and MJNA.” – Dean Petkanas, Founder and Chief Executive Officer of Kannalife Sciences, Inc.
“The companies work in the standardization of cannabis based products packaging, testing and identification is clearly where the industry is heading. We believe that Kannalife will be able to deploy its proprietary technology for standardization to markets that CannaVest and MJNA are currently in.” – Michael Mona, President of CannaVest
“From Kannalife’s inception, we have positioned ourselves as a innovative company focused on meeting the needs of a new paradigm shift in phyto-medicine. We believe this partnership lends to a great new opportunity and forward thinking approach to create standardization in this industry and beyond it.” – Thoma Kikis, Founder and Chief Visionary Officer of Kannalife.
About Medical Marijuana Inc. (OTC: MJNA):
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
About CannaVest (OTC: FCLS):
CannaVest is in the business of developing, producing, marketing and selling end consumer products containing the hemp based compounds with a focus on Cannabidiol (CBD). We seek to take advantage of an emerging worldwide trend to re-energize the production of industrial hemp and to foster its many uses for consumers. CBD is derived from hemp stalk and seed. This legal substance can be used with foods and nutritional supplements for consumer health and wellness benefits as well as in the pharmaceutical industry. The company anticipate launching our first product to large commercial buyers in early 2013, and having products on the market available to consumers shortly thereafter.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). For more information, please visit the company’s website at: www.kannalife.com
NEW YORK, March 7, 2013 — Kannalife Sciences, Inc. (“Kannalife”) the phyto-medical company that specializes in the research & development of pharmacological products derived from botanical sources, announced today the entry into Series A financing totaling $1.5 million.
The investment is led by and Medical Marijuana Inc. (OTC: MJNA) and CannaVest Corp. (OTC: FCLS).
“From Kannalife’s exclusive license with NIH to its years in development of standardization in packaging cannabis based products, lends a perfect fit for the Medical Marijuana Inc., family of companies. Particularly, the NIH exclusive license in our opinion is a true industry game changer. Our investment in Kannalife helps further build our pipeline of patented cannabinoid based medical products. In the very near future, it is patents such as this that we believe will determine a company’s future success in the cannabis based pharmaceutical industry.” – Michelle Sides, Chairman and Chief Operating Officer of Medical Marijuana Inc.
“The investments being made into Kannalife by CannaVest and MJNA go well beyond the actual dollars and cents.CannaVest and MJNA have paved highly sensible commercial inroads in the field of phyto-medics, and principally in the area of cannabinoid based medicaments. We are delighted to be part of the long range plans of both CannaVest and MJNA.” – Dean Petkanas, Founder and Chief Executive Officer of Kannalife Sciences, Inc.
“The companies work in the standardization of cannabis based products packaging, testing and identification is clearly where the industry is heading. We believe that Kannalife will be able to deploy its proprietary technology for standardization to markets that CannaVest and MJNA are currently in.” – Michael Mona, President of CannaVest
“From Kannalife’s inception, we have positioned ourselves as a innovative company focused on meeting the needs of a new paradigm shift in phyto-medicine. We believe this partnership lends to a great new opportunity and forward thinking approach to create standardization in this industry and beyond it.” – Thoma Kikis, Founder and Chief Visionary Officer of Kannalife.
About Medical Marijuana Inc. (OTC: MJNA):
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company’s website at: www.MedicalMarijuanaInc.com
About CannaVest (OTC: FCLS):
CannaVest is in the business of developing, producing, marketing and selling end consumer products containing the hemp based compounds with a focus on Cannabidiol (CBD). We seek to take advantage of an emerging worldwide trend to re-energize the production of industrial hemp and to foster its many uses for consumers. CBD is derived from hemp stalk and seed. This legal substance can be used with foods and nutritional supplements for consumer health and wellness benefits as well as in the pharmaceutical industry. The company anticipate launching our first product to large commercial buyers in early 2013, and having products on the market available to consumers shortly thereafter.
About Kannalife Sciences, Inc.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”). For more information, please visit the company’s website at: www.kannalife.com
Kannalife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
NEW YORK, July 9, 2012 — Kannalife Sciences, Inc. (“Kannalife”) Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”).
The ‘507 Patent includes among other things, claims directed to a method of treating diseases caused by oxidative stress by administering a therapeutically effective amount of a non-psychoactive cannabinoid that has substantially no binding to the NMDA receptor. Cannabinoids are any of a group of related compounds that include cannabinol and the active constituents of cannabis (marijuana).
Pursuant to the terms of the exclusive license with NIH-OTT, Kannalife intends to move forward with its commercial development plan, and design a novel new drug compound for the treatment of Hepatic Encephalopathy (HE). Kannalife believes its target drug candidate will be comprised of one or more cannabinoid(s) for use and delivery in humans as FDA approved drugs. Currently, in the United States, there are over 1.5 million sufferers of Hepatic Encephalopathy,
Dean Petkanas, Founder and CEO of Kannalife Sciences, Inc. stated, “We are very proud of our efforts to date in designing a rational and viable commercial development plan for a target therapeutic with a potentially new and exciting mechanism of action. We are greatly appreciative of the efforts put forth by the dedicated professionals and scientists at NIH-OTT who worked with us during the licensing process, and for helping to bring the exclusive licensing of the ‘507 Patent to a successful conclusion. We believe the initiatives put forth by President Obama and his administration regarding small business played a big role in providing Kannalife with the opportunity of competing in an equitable licensing arena.”
About the NIH Office of Technology Transfer (NIH-OTT):
NIH-OTT manages the patenting and licensing of a wide range of inventions made by scientists working for the NIH and FDA intramural research programs as mandated by the Federal Technology Transfer Act.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.
NEW YORK, July 9, 2012 — Kannalife Sciences, Inc. (“Kannalife”) Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent 6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants” (the “‘507 Patent”).
The ‘507 Patent includes among other things, claims directed to a method of treating diseases caused by oxidative stress by administering a therapeutically effective amount of a non-psychoactive cannabinoid that has substantially no binding to the NMDA receptor. Cannabinoids are any of a group of related compounds that include cannabinol and the active constituents of cannabis (marijuana).
Pursuant to the terms of the exclusive license with NIH-OTT, Kannalife intends to move forward with its commercial development plan, and design a novel new drug compound for the treatment of Hepatic Encephalopathy (HE). Kannalife believes its target drug candidate will be comprised of one or more cannabinoid(s) for use and delivery in humans as FDA approved drugs. Currently, in the United States, there are over 1.5 million sufferers of Hepatic Encephalopathy,
Dean Petkanas, Founder and CEO of Kannalife Sciences, Inc. stated, “We are very proud of our efforts to date in designing a rational and viable commercial development plan for a target therapeutic with a potentially new and exciting mechanism of action. We are greatly appreciative of the efforts put forth by the dedicated professionals and scientists at NIH-OTT who worked with us during the licensing process, and for helping to bring the exclusive licensing of the ‘507 Patent to a successful conclusion. We believe the initiatives put forth by President Obama and his administration regarding small business played a big role in providing Kannalife with the opportunity of competing in an equitable licensing arena.”
About the NIH Office of Technology Transfer (NIH-OTT):
NIH-OTT manages the patenting and licensing of a wide range of inventions made by scientists working for the NIH and FDA intramural research programs as mandated by the Federal Technology Transfer Act.
Kannalife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent 6,630,507, entitled “Cannabinoids as antioxidants and neuroprotectants” and PCT Application Serial No. PCT/US99/08769 and foreign equivalents thereof, entitled “Cannabinoids as antioxidants and neuroprotectants” [HHS Ref. No. E-287-1997/2] to Kannalife Sciences Inc., which has offices in New York, U.S. This patent and its foreign counterparts have been assigned to the Government of the United States of America.
The prospective exclusive license territory may be worldwide, and the field of use may be limited to:
The development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, for the treatment of hepatic encephalopathy, as claimed in the Licensed Patent Rights.
DATES:
Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 19, 2011 will be considered.
SUPPLEMENTARY INFORMATION:
The technology describes pharmaceutical compositions of cannabinoids that are useful as tissue protectants, such as neuroprotectants and cardioprotectants. The cannabinoids compounds may be used, for example, in the treatment of acute ischemic neurological insults or chronic neurodegenerative diseases. Nonpsychoactive cannabinoids, such as Cannabidiol (CBD), are particularly advantageous since they avoid toxicity that is encountered with psychoactive cannabinoids at high doses.
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7.Show citation box
Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: November 10, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 2011-29726 Filed 11-16-11; 8:45 am]
BILLING CODE 4140-01-P
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent 6,630,507, entitled “Cannabinoids as antioxidants and neuroprotectants” and PCT Application Serial No. PCT/US99/08769 and foreign equivalents thereof, entitled “Cannabinoids as antioxidants and neuroprotectants” [HHS Ref. No. E-287-1997/2] to Kannalife Sciences Inc., which has offices in New York, U.S. This patent and its foreign counterparts have been assigned to the Government of the United States of America.
The prospective exclusive license territory may be worldwide, and the field of use may be limited to:
The development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, for the treatment of hepatic encephalopathy, as claimed in the Licensed Patent Rights.
DATES:
Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 19, 2011 will be considered.
SUPPLEMENTARY INFORMATION:
The technology describes pharmaceutical compositions of cannabinoids that are useful as tissue protectants, such as neuroprotectants and cardioprotectants. The cannabinoids compounds may be used, for example, in the treatment of acute ischemic neurological insults or chronic neurodegenerative diseases. Nonpsychoactive cannabinoids, such as Cannabidiol (CBD), are particularly advantageous since they avoid toxicity that is encountered with psychoactive cannabinoids at high doses.
The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7.Show citation box
Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: November 10, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 2011-29726 Filed 11-16-11; 8:45 am]
BILLING CODE 4140-01-P
